

10/513699

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaeal1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified  
prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new  
custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days  
of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current  
U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental  
spectra  
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.  
applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new  
predefined hit display formats  
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements  
NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family  
searching  
NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology  
sequence search option  
  
NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

<12/04/2007>

Erich Leese

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:54:37 ON 03 JUN 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:54:48 ON 03 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JUN 2008 HIGHEST RN 1024742-83-3  
DICTIONARY FILE UPDATES: 2 JUN 2008 HIGHEST RN 1024742-83-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10539708new.str



```

chain nodes :
29 30 31 32 33 35 36 37 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28
chain bonds :
2-31 7-30 10-26 18-32 22-33 23-29 29-30 29-35 29-36 30-37 30-38
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-19 6-21 7-8 7-12 8-9 9-10 10-11 11-12 13-14
13-18 14-15 14-26 15-16 15-28 16-17 17-18 19-20 19-22 20-21 20-25 22-23
23-24 24-25 26-27 27-28
exact/norm bonds :
1-2 1-6 2-3 2-31 3-4 4-5 5-6 7-8 7-12 7-30 8-9 9-10 10-11 10-26 11-12
19-20 19-22 20-25 22-23 22-33 23-24 23-29 24-25 26-27
exact bonds :
5-19 6-21 14-26 15-28 18-32 20-21 27-28 29-30 29-35 29-36 30-37 30-38
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS

```

L1 STRUCTURE UPLOADED

10/513699

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 16:55:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 44 TO ITERATE

100.0% PROCESSED 44 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L2

2 SEA SSS FUL L1

=> file capluis

'CAPLUIS' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'REGISTRY'

Enter "HELP FILE NAMES" at an arrow prompt (=) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 16:55:18 ON 03 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jun 2008 VOL 148 ISS 23

FILE LAST UPDATED: 2 Jun 2008 (20080602/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l2 full

L3 1 L2

<12/04/2007>

Erich Leese

10/513699


=> d ibib abs hitstr

<12/04/2007>


Erich Leese

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:525895 CAPLUS  
 DOCUMENT NUMBER: 141:89095  
 TITLE: Preparation of 3-substituted 3,4-dihydrothieno[2,3-d]pyrimidin-4-ones as central nervous system agents  
 PATENT ASSIGNEE(S): Abbott GmbH & Co. Kg, Germany  
 SOURCE: Ger. Offen., 32 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10259382	A1	20040701	DE 2002-10259382	20021218
WO 2004055024	A1	20040701	WO 2003-EP14423	20031217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003300529	A1	20040709	AU 2003-300529	20031217
EP 1572698	A1	20050914	EP 2003-813137	20031217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20060142317	A1	20060629	US 2005-539708	20051230
PRIORITY APPLN. INFO.:			DE 2002-10259382	A 20021218
			WO 2003-EP14423	W 20031217
OTHER SOURCE(S):	MARPAT 141:89095			
GI				



I



II

AB Title compds. [I; A = O, S, SO, NR5, CH2; R5 = N, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl; R4 = H, Me; m, n = 0, 1; R1 = alkylene; R2 = 1,4-piperazinylene, 1,4-piperidinylene, 1,3-pyrrolidinylene, 1,4-homopiperazinylene, etc.; R3 = (substituted) (aryl- or heteroaryl-condensed) 5-membered heteroaryl], were prepared. Thus, title compound (II) bound to 5-HT1A and 5-HT1B receptors with Ki = 0.5 nM and 0.6 nM, resp.


IT 713508-93-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dihydrothienopyrimidinones as central nervous system agents)

RN 713508-93-1 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

10/513699



<12/04/2007>

Erich Leese

10/513699

=>

Uploading C:\Program Files\Stnexp\Queries\10539708.str



```
chain nodes :
13 20 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
4-13 5-22 6-20
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 8-10 9-12 10-11 11-12
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 4-13 5-6 5-22 6-20 7-8 8-9 8-10 9-12
10-11 11-12
isolated ring systems :
containing 1 :
```

G1:O,S,N,CH2

G2:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 20:CLASS 22:CLASS

L4 STRUCTURE UPLOADED


=> d 14

<12/04/2007>

Erich Leese

10/513699

L4 HAS NO ANSWERS  
L4 STR



G1 O, S, N, CH2  
G2 H, Me

Structure attributes must be viewed using STN Express query preparation.

=> s l4 full  
REGISTRY INITIATED  
Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 16:56:01 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 31984 TO ITERATE

100.0% PROCESSED 31984 ITERATIONS 4283 ANSWERS  
SEARCH TIME: 00.00.02

L5 4283 SEA SSS FUL L4

L6 44 L5

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.48	363.34
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'CAPLUS' ENTERED AT 16:56:09 ON 03 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jun 2008 VOL 148 ISS 23

FILE LAST UPDATED: 2 Jun 2008 (20080602/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l6 full

L7 44 L5

=> d ibib abs hitstr tot

L7 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1066126 CAPLUS

DOCUMENT NUMBER: 147:522185

TITLE: Synthesis of isomeric enamine derivatives of fused cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones.

AUTHOR(S): Stereoelectronic effect on the regioselectivity Lilienkamp, Annamaria; Heikkinen, Sami; Mutikainen, Ilpo; Wahala, Kristiina

CORPORATE SOURCE: Laboratory of Organic Chemistry, Department of Chemistry, University of Helsinki, Helsinki, 00014, Finland

SOURCE: Synthesis (2007), (17), 2699-2705

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:522185

AB A regioselective synthesis of enamine and enaminone derivs. of fused cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones is reported. The enamine vs. enaminone product in the condensation reaction with N,N-dimethylformamide dimethylacetal (DMFDMA) was shown to depend on the conformation of the cycloalkeno ring fused to the pyrimidinone moiety. The ring conformation and the stereoelectronic effect of the amidine  $\alpha$ -protons were studied by X-ray crystallog. In deuterium exchange expts., the amidine-ketene-N,N-acetal tautomerism was shown to be prohibited with larger ring systems consequently yielding the enaminone products.


IT 101662-28-6P 813458-88-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(regioselective synthesis of isomeric enamine derivs. of fused cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones)

RN 101662-28-6 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,3-dimethyl- (CA INDEX NAME)



RN 813458-88-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-2,3-dimethyl- (CA INDEX NAME)

10/513699




REFERENCE COUNT:

43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:484949 CAPLUS  
 DOCUMENT NUMBER: 146:475681  
 TITLE: Immunomodulatory heterocyclic compounds that target  
 and inhibit the pY binding site of tyrosine kinase  
 p56lck SH2 domain  
 INVENTOR(S): Mackereell, Alexander; Hayashi, Jun  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 90pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070099970	A1	20070503	US 2006-507038	20060821
WO 2008024759	A2	20080228	WO 2007-US76402	20070821
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2005-709972P	P 20050819
			US 2006-507038	A 20060821
OTHER SOURCE(S): MARPAT 146:475681				
AB Small mol.-weight non-peptidic compds. block lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.				
IT 442674-70-6 442674-72-8 442675-13-0				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (immunomodulatory heterocyclic compound inhibitors of pY binding site of tyrosine kinase p56lck SH2 domain)				
RN 442674-70-6 CAPLUS				
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-[3-[(2,4- dimethoxyphenyl)amino]-3-oxopropyl]-5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)				



RN 442674-72-8 CAPLUS


10/513699

CN [1]Benzo[h]thieno[2,3-d]pyrimidine-3(4H)-acetamide, N-[3-[(3,4-dimethoxyphenyl)amino]-3-oxopropyl]-5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 442675-13-0 CAPLUS


CN [1]Benzo[h]thieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-N-[3-[(2-methoxy-5-methylphenyl)amino]-3-oxopropyl]-4-oxo- (CA INDEX NAME)




L7 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:433840 CAPLUS  
 DOCUMENT NUMBER: 146:441502  
 TITLE: Composition and synthesis of new benzamides and related compounds for inhibition of HIV replication  
 INVENTOR(S): Rana, Tariq M.  
 PATENT ASSIGNEE(S): University of Massachusetts, USA  
 SOURCE: PCT Int. Appl., 160pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007044565	A2	20070419	WO 2006-US39228	20061006
WO 2007044565	A3	20070607		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20070099919	A1	20070503	US 2006-544068	20061006
PRIORITY APPLN. INFO.:			US 2005-725043P	P 20051006
OTHER SOURCE(S):	MARPAT 146:441502			

GI




I



II

- AB The invention provides compds. of formula I and compns. for inhibiting Vif and methods for treating viral infection, e.g., HIV infection. Compds. of formula I wherein R is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (hetero)aryl, and (un)substituted (hetero)cycloalkyl; R1, R2 and R3 are independently H, NO2, NH2, CF3, Br, Cl, F and I; Y is CO, NHCO and derivs., SO2NH and derivs., NHCONH, NHC(=O)2, OCONH and CONH2 and derivs.; Z is absent, O, S, NH and derivs., CH2, SO2, C1-6 alkyl-OH and derivs., CO, C1-6 alkyl-NH and derivs.; and their enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 2-iodobenzoyl chloride with 2-methoxyaniline; the resulting N-(2-methoxyphenyl)-2-iodobenzamide underwent sulfanylation with 4-nitrothiophenol to give compound II. All the invention compds. were evaluated for their Vif inhibitory activity. These compound may be useful in the treatment of viral infection such as HIV infections.
- IT 455920-07-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of arylsulfanylbzamidates and related compds. as Vif inhibitors useful in the treatment of HIV infections)
- RN 455920-07-7 CAPLUS
- CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-(2-ethoxyphenyl)-5,6,7,8-tetrahydro-7-methyl-4-oxo- (CA INDEX NAME)



L7 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:922111 CAPLUS

DOCUMENT NUMBER: 145:306767

TITLE: Thienyl compounds for treating virus-related conditions

INVENTOR(S): Olivo, Paul D.; Buscher, Benjamin A.; Dyall, Julie; Jockel-Balsarotti, Jennifer I.; O'Guin, Andrew K.; Roth, Robert M.; Franklin, Gary W.; Starkey, Gale W.

PATENT ASSIGNEE(S): Apath, LLC, USA

SOURCE: PCT Int. Appl., 343pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006093518	A2	20060908	WO 2005-US22559	20050625
WO 2006093518	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-582996P P 20040625

OTHER SOURCE(S): MARPAT 145:306767

AB The invention discloses thienyl compds. (particularly (thien-2-yl)amino compds.), pharmaceutical compns. and kits comprising such compds., and uses of such compds. for preparing medicaments and treating virus-related conditions in animals.

IT 369394-92-3 370853-41-1 384351-55-7

433254-84-3 433975-50-9 449190-71-0

449190-92-5 459416-27-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(thienyl compds. for treating virus-related conditions)

RN 369394-92-3 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-7-methyl-4-oxo-, (1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazide (9CI) (CA INDEX NAME)

10/513699




RN 370853-41-1 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)hydrazide (9CI) (CA INDEX NAME)



RN 384351-55-7 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-(2-furanylmethyl)-5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 433254-84-3 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro- $\alpha$ -methyl-4-oxo-, methyl ester (CA INDEX NAME)

10/513699




RN 433975-50-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-(2-furanylmethyl)-5,6,7,8-tetrahydro-7-methyl-4-oxo- (CA INDEX NAME)




RN 449190-71-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid,  $\alpha$ -ethyl-5,6,7,8-tetrahydro-4-oxo-, 2-methylpropyl ester (CA INDEX NAME)



RN 449190-92-5 CAPLUS


CN Benzo[b]thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-6-methyl-2-[[2-(5,6,7,8-tetrahydro-7-methyl-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]amino]-, ethyl ester (CA INDEX NAME)



RN 459416-27-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro- $\alpha$ ,7-dimethyl-4-oxo-, cyclohexyl ester (CA INDEX NAME)


10/513699



<12/04/2007>

Erich Leese

L7 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1178247 CAPLUS  
 DOCUMENT NUMBER: 144:69793  
 TITLE: Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs  
 AUTHOR(S): Kling, Andreas; Lange, Udo E. W.; Mack, Helmut; Bakker, Margot H. M.; Drescher, Karla U.; Hornberger, Wilfried; Hutchins, Charles W.; Moeller, Achim; Mueller, Reinhold; Schmidt, Martin; Unger, Liliane; Wicke, Karsten; Schellhaas, Kurt; Steiner, Gerd  
 CORPORATE SOURCE: Neuroscience Discovery, Abbott GmbH & Co. KG, Ludwigshafen, D-67008, Germany  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(24), 5567-5573  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 144:69793  
 GI




- AB 5-HT1 autoreceptor ligands based on the N-4-aryl-piperazinyl-N'-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a mode of action the objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT1A and 5-HT1B receptors. Strategies for the development of dual 5-HT1A and 5-HT1B antagonists based on 2-methoxyphenyl- or isoquinoline substituted piperazine derivs. as leads and the corresponding results are discussed. Isoquinoline analog I displayed high affinity and an antagonistic mode of action for the 5-HT1A and the 5-HT1B receptors and was characterized further with respect to selectivity, elec. stimulated [3H]5-HT release and in vivo efficacy.
- IT 281657-31-6P 281657-43-0P 281657-46-3P  
 281657-47-4P 385821-43-2P 708972-34-3P  
 743409-73-6P 750559-17-2P 754965-99-6P  
 759446-14-5P 766496-55-3P 773043-17-7P  
 786629-89-8P 792895-04-6P 872005-20-4P  
 872005-21-5P 872005-22-6P 872005-23-7P  
 872005-24-8P 872005-25-9P 872005-26-0P

872005-27-1P 872005-28-2P 872005-29-3P  
 872005-35-1P 872005-36-2P 872005-37-3P  
 872005-38-4P 872005-39-5P 872005-40-8P  
 872005-41-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation, 5-HT1A and 5-HT1B antagonistic activity, antidepressant activity, and SAR of (arylpiperazinylethyl)tetrahydropyridothienopyrimidinones using heterocyclization and amination with arylpiperazines as the key steps)


RN 281657-31-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(4-methoxy[1,1'-biphenyl]-3-yl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)




RN 281657-43-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-quinoliny)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-46-3 CAPLUS


CN Benzonitrile, 2-[4-[2-(5,6,7,8-tetrahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 281657-47-4 CAPLUS


10/513699

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 385821-43-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(8-quinoliny)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 708972-34-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(4-isoquinoliny)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)




RN 743409-73-6 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 750559-17-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-  
[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)

RN 754965-99-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,5-  
dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA  
INDEX NAME)


RN 759446-14-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-  
methyl-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 766496-55-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 773043-17-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,5-dichloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 786629-89-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)




RN 792895-04-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(4-quinazolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 872005-20-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(4-[1,1'-biphenyl]-2-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 872005-21-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 872005-22-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-[2-(2,2-dimethylpropoxy)phenyl]-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 872005-23-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[2-(phenoxymethyl)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 872005-24-8 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[2-(phenylmethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



10/513699


RN 872005-25-9 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-5-methylphenyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)




RN 872005-26-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-5-(trifluoromethyl)phenyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 872005-27-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4-chloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-28-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3-chloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)

10/513699




RN 872005-29-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4,5-dichloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-35-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,3-dihydro-7-benzofuranyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-36-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(4-benzo[b]thien-7-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)

10/513699




RN 872005-37-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[(1-isoquinolinyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)




RN 872005-38-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(4-quinoliny)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 872005-39-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-quinoliny)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 872005-40-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(4-(5-isoquinoliny)-1-piperazinyl)ethyl]-7-methyl- (CA INDEX NAME)



RN 872005-41-9 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(4-(8-isoquinoliny)-1-piperazinyl)ethyl]-7-methyl- (CA INDEX NAME)



IT 281657-01-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, 5-HT1A and 5-HT1B antagonistic activity, antidepressant activity, and SAR of (aryl)piperazinylethyl)tetrahydropyrido[2,3-d]thienopyrimidinones using heterocyclization and amination with arylpiperazines as the key steps)

RN 281657-01-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)

10/513699



REFERENCE COUNT:

47

THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2005:395446 CAPLUS

DOCUMENT NUMBER: 142:406543

TITLE: TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators

INVENTOR(S): Xu, Wei; Zheng, Wentao; Baly, Deborah Lynn; Galan, Adam Antoni; Ibrahim, Mohamed Abdulkader; Jaeger, Christopher; Kearney, Patrick; Leahy, James William; Lewis, Gary Lee; McMillan, Kirk; Noguchi, Robin; Tammie, Nuss, John M.; Parks, Jason Jevious; Schnepp, Kevin Luke; Shi, Xian; Williams, Matthew Alan

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040355	A2	20050506	WO 2004-US35469	20041022
WO 2005040355	A3	20050804		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004283313	A1	20050506	AU 2004-283313	20041022
CA 2542064	A1	20050506	CA 2004-2542064	20041022
EP 1678121	A2	20060712	EP 2004-796442	20041022
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007527412	T	20070927	JP 2006-536928	20041022
US 20070208166	A1	20070906	US 2006-576932	20061019
PRIORITY APPLN. INFO.:			US 2003-514377P	P 20031024
			WO 2004-US35469	W 20041022

OTHER SOURCE(S): MARPAT 142:406543

AB The invention provides compds. and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. Thus, N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,d][1,4]diazepine-3-carboxamide was synthesized. This compound exhibited an IC50 with JIK kinase of <50 nM and an IC50 with TAO kinase of between 50 and 500 nM.


10/513699

IT 442675-24-3

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(TAO kinase inhibitors for pharmaceutical use and for screening for  
kinase modulators)



RN 442675-24-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-N-[4-  
[(6-methoxy-2-benzothiazolyl)amino]-4-oxobutyl]-4-oxo- (CA INDEX NAME)



L7 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:1124651 CAPLUS  
 DOCUMENT NUMBER: 142:74590  
 TITLE: Preparation of fused thienopyrimidinones as  
 17 $\beta$ -hydroxysteroid dehydrogenase (17 $\beta$ -HSD)  
 inhibitors  
 INVENTOR(S): Waehaelae, Kristiina; Lilienkamp, Annamaria; Alho,  
 Sari; Huhtinen, Kaisa; Johansson, Nina; Koskimies,  
 Pasi; Viikko, Kimmo  
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B. V., Neth.  
 SOURCE: PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110459	A1	20041223	WO 2004-EP6231	20040609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050032778	A1	20050210	US 2004-861922	20040607
AU 2004246791	A1	20041223	AU 2004-246791	20040609
CA 2527591	A1	20041223	CA 2004-2527591	20040609
EP 1635840	A1	20060322	EP 2004-739738	20040609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1784234	A	20060607	CN 2004-80012636	20040609
BR 2004011319	A	20060718	BR 2004-11319	20040609
JP 2006527227	T	20061130	JP 2006-515870	20040609
MX 2005PA12871	A	20060731	MX 2005-PA12871	20051129
US 20080103131	A1	20080501	US 2007-967989	20071231
PRIORITY APPLN. INFO.:			US 2003-477017P	P 20030610
			US 2004-861922	A3 20040607
			WO 2004-EP6231	W 20040609
OTHER SOURCE(S):	MARPAT 142:74590			
GI				



AB Use of title compds. [I; R1, R2 = H, alkyl; R1R2 = atoms to form a 5-8 membered (substituted) (heterocyclic) (unsatd.) ring; R3R4 = atoms to form a 5-8 membered (substituted) (unsatd.) ring; with provisos] for manufacture of a medicament for the treatment/prevention of a steroid hormone dependent disease requiring the inhibition of 17 $\beta$ -hydroxysteroid dehydrogenase is claimed. Thus, Et 2-amino-4,5,6,7-tetrahydrobenzothiophene-3-carboxylate,  $\epsilon$ -caprolactam, and POC13 were refluxed in CH<sub>2</sub>Cl<sub>2</sub> to give 90% title compound (II). II at 10  $\mu$ M gave 45.9% inhibition of 17 $\beta$ -HSD type 1.


IT 813458-88-7P 813458-89-8P 813458-93-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of fused thienopyrimidinones as 17 $\beta$ -hydroxysteroid dehydrogenase inhibitors)


RN 813458-88-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-2,3-dimethyl-  
(CA INDEX NAME)



RN 813458-89-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 3-ethyl-6,7-dihydro-  
(CA INDEX NAME)




RN 813458-93-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-7-carboxaldehyde, 8-chloro-3,4,5,6,7,8-

10/513699

hexahydro-3-methyl-4-oxo- (CA INDEX NAME)




IT 40277-29-0P 101662-28-6P 813459-10-8P  
813459-14-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of fused thienopyrimidinones as  $17\beta$ -hydroxysteroid  
dehydrogenase inhibitors)


RN 40277-29-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-methyl-  
(CA INDEX NAME)



RN 101662-28-6 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,3-dimethyl-  
(CA INDEX NAME)



RN 813459-10-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-3-methyl-  
(CA INDEX NAME)



L7 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1038771 CAPLUS

DOCUMENT NUMBER: 143:286364

TITLE: Synthesis of certain propanolamines as potential adrenoceptor antagonists

AUTHOR(S): Khalil, N. A.; Botros, S.; Soliman, L. N.; Amin, F. M.; El-Zanfaly, S.

CORPORATE SOURCE: Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt

SOURCE: Bulletin of the Faculty of Pharmacy (Cairo University) (2002), 40(2), 23-29

CODEN: BFPHAS; ISSN: 1110-0931


PUBLISHER: Cairo University, Faculty of Pharmacy

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:286364

GI



AB Amino(hydroxy)-functionalized hexahydrobenzo[b]thieno[2,3-d]pyrimidinones I (X = CH<sub>2</sub>, R<sub>1</sub> = H; X = 1,4-C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>, R<sub>1</sub> = Me; R<sub>2</sub> = H, R<sub>3</sub> = n-Pr, Me<sub>2</sub>CH, Me<sub>3</sub>C, PhCH<sub>2</sub>, PhCH<sub>2</sub>CH<sub>2</sub>, cyclopentyl; R<sub>2</sub> = R<sub>3</sub> = Et, PhCH<sub>2</sub>; R<sub>2</sub>R<sub>3</sub>N = 1-pyrrolidinyl, 4-morpholinyl, 1-piperidinyl) were synthesized by ring opening of epoxides II with the corresponding primary and secondary amines. Pharmacol. screening showed that the compds. I (X = CH<sub>2</sub>, R<sub>1</sub> = H; X = 1,4-C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>, R<sub>1</sub> = Me; R<sub>2</sub>R<sub>3</sub>N = 1-pyrrolyl, 1-piperidinyl) produced initial myocardial depressant effect, however only compds. I (X = 1,4-C<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>; R<sub>1</sub> = Me; R<sub>2</sub>R<sub>3</sub>N = 1-pyrrolidinyl, 1-piperidinyl) antagonized the stimulant effect of isoprenaline on isolated frog heart.


IT 864234-08-2P 864234-10-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of amino(hydroxy)propyl-functionalized hexahydrobenzo[b]thieno[2,3-d]pyrimidinones as myocardial depressants and adrenoceptor antagonists via epoxide ring opening with amines)

RN 864234-08-2 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



10/513699

RN 864234-10-6 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-(1-piperidinyl)propyl]- (CA INDEX NAME)




IT 864234-03-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino(hydroxy)propyl-functionalized hexahydrobenzo[b]thieno[2,3-d]pyrimidinones as myocardial depressants and adrenoceptor antagonists via epoxide ring opening with amines)

RN 864234-03-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-oxiranylmethyl)- (CA INDEX NAME)



IT 864234-02-6P 864234-04-8P 864234-05-9P

864234-06-0P 864234-07-1P 864234-09-3P


864234-11-7P 864234-12-8P 864234-13-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of amino(hydroxy)propyl-functionalized hexahydrobenzo[b]thieno[2,3-d]pyrimidinones as myocardial depressants and adrenoceptor antagonists via epoxide ring opening with amines)

RN 864234-02-6 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4-one, 3,3'-(2-hydroxy-1,3-propanediyl)bis[5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 864234-04-8 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-(proplylamino)propyl]- (CA INDEX NAME)

10/513699




RN 864234-05-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-[(1-methylethyl)amino]propyl]- (CA INDEX NAME)




RN 864234-06-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(diethylamino)-2-hydroxypropyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864234-07-1 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864234-09-3 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(cyclopentylamino)-2-hydroxypropyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)

10/513699




RN 864234-11-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-[(phenylmethyl)amino]propyl]- (CA INDEX NAME)




RN 864234-12-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-[(2-phenylethyl)amino]propyl]- (CA INDEX NAME)



RN 864234-13-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-[[bis(phenylmethyl)amino]-2-hydroxypropyl]-5,6,7,8-tetrahydro-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT:

13


THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

<12/04/2007>


Erich Leese

L7 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:525895 CAPLUS  
 DOCUMENT NUMBER: 141:89095  
 TITLE: Preparation of 3-substituted 3,4-dihydrothieno[2,3-d]pyrimidin-4-ones as central nervous system agents  
 PATENT ASSIGNEE(S): Abbott GmbH & Co. Kg, Germany  
 SOURCE: Ger. Offen., 32 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10259382	A1	20040701	DE 2002-10259382	20021218
WO 2004055024	A1	20040701	WO 2003-EP14423	20031217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003300529	A1	20040709	AU 2003-300529	20031217
EP 1572698	A1	20050914	EP 2003-813137	20031217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20060142317	A1	20060629	US 2005-539708	20051230
PRIORITY APPLN. INFO.:			DE 2002-10259382	A 20021218
			WO 2003-EP14423	W 20031217
OTHER SOURCE(S):	MARPAT 141:89095			
GI				



I



II

AB Title compds. [I; A = O, S, SO, NR5, CH2; R5 = N, alkyl, aryl, aralkyl, acyl, alkoxy carbonyl; R4 = H, Me; m, n = 0, 1; R1 = alkylene; R2 = 1,4-piperazinylenes, 1,4-piperidinylenes, 1,3-pyrrolidininylenes, 1,4-homopiperazinylenes, etc.; R3 = (substituted) (aryl- or heteroaryl-condensed) 5-membered heteroaryl], were prepared. Thus, title compound (II) bound to 5-HT1A and 5-HT1B receptors with Ki = 0.5 nM and 0.6 nM, resp.

IT 713508-85-1P 713508-86-2P 713508-87-3P  
713508-88-4P 713508-89-5P 713508-90-8P  
713508-91-9P 713508-92-0P 713508-93-1P  
713508-94-2P 713508-95-3P 713508-96-4P  
713508-97-5P 713508-98-6P 713508-99-7P  
713509-00-3P 713509-01-4P 713509-02-5P  
713509-03-6P 713509-04-7P 713509-06-9P  
713509-08-1P 713509-09-2P 713509-10-5P  
713509-11-6P 713509-12-7P 713509-13-8P  
713509-14-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dihydrothienopyrimidinones as central nervous system agents)

RN 713508-85-1 CAPLUS


CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 713508-84-0

CMF C23 H25 N5 O3 S

10/513699



CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 713508-86-2 CAPLUS


CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 713508-87-3 CAPLUS

CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[(1S)-1-methyl-2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 713508-88-4 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-

(CA INDEX NAME)




RN 713508-89-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4-chloro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-  
(CA INDEX NAME)




RN 713508-90-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[5-(trifluoromethyl)-2-benzothiazolyl]-1-piperazinyl]ethyl]-  
(CA INDEX NAME)




RN 713508-91-9 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-2-benzothiazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 713508-92-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzimidazol-2-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713508-93-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 713508-94-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-benzoxazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 713508-95-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-benzothiazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713508-96-4 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 713508-97-5 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



10/513699

RN 713508-98-6 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(7-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713508-99-7 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-methoxy-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-00-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-methoxy-1-methyl-1H-indol-3-yl)-1-piperidinyl]ethyl]-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

10/513699


RN 713509-01-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-3-benzofuranyl)-1-piperidinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 713509-02-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-3-benzofuranyl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 713509-03-6 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1H-indol-3-yl)-1-piperidinyl]ethyl]-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



10/513699

RN 713509-04-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 713509-06-9 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 713509-05-8

CMF C24 H26 N6 O S



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 713509-08-1 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1-piperidinyl]ethyl]-, acetate (1:1) (CA INDEX NAME)


CM 1

CRN 713509-07-0

CMF C24 H28 N6 O S




10/513699




● HCl

RN 713509-11-6 CAPLUS  
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzotriazol-1-yl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 713509-12-7 CAPLUS  
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 713509-13-8 CAPLUS

10/513699

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1-phenyl-1H-tetrazol-5-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 713509-14-9 CAPLUS

CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[(1R)-1-methyl-2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 713509-15-0 713509-16-1 713509-17-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of dihydrothienopyrimidinones as central nervous system agents)

RN 713509-15-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(4-benzo[b]thien-3-yl-3,6-dihydro-1(2H)-pyridinyl)ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




<12/04/2007>

Erich Leese

10/513699

RN 713509-16-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,1-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-17-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(5-methoxy-1H-indol-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




IT 281657-00-9P 281657-01-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydrothienopyrimidinones as central nervous system agents)

RN 281657-00-9 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-hydroxyethyl)-7-methyl- (CA INDEX NAME)



RN 281657-01-0 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)

10/513699



L7 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:31458 CAPLUS  
 DOCUMENT NUMBER: 136:85831  
 TITLE: Preparation of 5,6,7,8-tetrahydropyrido[4',  
 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-ones for the  
 treatment of cerebral ischemia  
 INVENTOR(S): Steiner, Gerd; Schellhaas, Kurt; Szabo, Laszlo; Behl,  
 Berthold; Garcia-Ladona, Francisco Javier; Unger,  
 Liliane  
 PATENT ASSIGNEE(S): Knoll Ag, Germany  
 SOURCE: PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002569	A1	20020110	WO 2001-EP7573	20010702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 10031389 A1 20020117 DE 2000-10031389 20000703 PRIORITY APPLN. INFO.: DE 2000-10031389 A 20000703 OTHER SOURCE(S): MARPAT 136:85831 GI				



I

AB Title compds. [I; R1 = H, C1-4 alkyl] and salts thereof were prepared as 5-HT1A agonists. Thus, a mixture of 3-(2-chloroethyl)-7-acetyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 8-(1-piperazinyl)quinoline (preparation given) and K2CO3 in xylene was refluxed for 18 h to give 7-acetyl-3-[2-(4-(8-quinolinyl)-1-piperazinyl)ethyl]-5,6,7,8-[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one which was refluxed with 15% HCl for 3 h to give 7% 3-[2-(4-(8-quinolinyl)-1-piperazinyl)ethyl]-5,6,7,8-[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one. Tested I showed affinity for the 5-HT1A receptor with  $K_i = 0.15-0.95$  nM in

10/513699

HEK 293 cells.


IT 385821-43-2P 385821-46-5P 385821-47-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydropyridothienopyrimidinones for treatment of cerebral ischemia)


RN 385821-43-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 385821-46-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 385821-47-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 281657-01-0 385821-42-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of tetrahydropyridothienopyrimidinones for treatment of  
 cerebral ischemia)  
 RN 281657-01-0 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-  
 5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 385821-42-1 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-3-(2-  
 chloroethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)



IT 385821-41-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of tetrahydropyridothienopyrimidinones for treatment of  
 cerebral ischemia)  
 RN 385821-41-0 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-  
 tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

10/513699




REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:31457 CAPLUS  
 DOCUMENT NUMBER: 136:102403  
 TITLE: Preparation of fused thieno[2,3-d]pyrimidines for the treatment of cerebral ischemia  
 INVENTOR(S): Steiner, Gerd; Schellhaas, Kurt; Szabo, Laszlo; Behl, Berthold; Garcia-Ladona, Francisco Javier; Unger, Lilliane  
 PATENT ASSIGNEE(S): Knoll G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002568	A1	20020110	WO 2001-EP7569	20010702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 10031390 A1 20020117 DE 2000-10031390 20000703 PRIORITY APPLN. INFO.: DE 2000-10031390 A 20000703 OTHER SOURCE(S): CASREACT 136:102403; MARPAT 136:102403 GI				



I


- AB Title compds. [I; A = O; B = H, Me; DE = (substituted) (CH<sub>2</sub>)<sub>3</sub>, (CH<sub>2</sub>)<sub>4</sub>; X = N; Y = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, (CH<sub>2</sub>)<sub>3</sub>, CH<sub>2</sub>CH; Z = N, C, CH; n = 2-4; R<sub>2</sub> = (substituted) (anellated) Ph, pyridyl, pyrimidinyl, pyrazinyl] and salts thereof were prepared as 5-HT<sub>1A</sub> agonists. Thus, a mixture of 2-ethoxymethylidenylamino-3-carbonylethoxy-4,7-dihydro-5H-thieno[2,3-d]pyran (preparation given) and 2-[4-(1-isoquinolinyl)-1-piperazinyl]ethylamine (preparation given) in EtOH was refluxed followed for stirring for 3 days at room temperature to give 89% 3-[2-(4-(1-isoquinolinyl)-1-piperazinyl)ethyl]-3,5,6,8-tetrahydro-4H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one. Tested I showed affinity for 5-HT<sub>1A</sub> receptors with K<sub>i</sub> = 0.16-3.30 nM in HEK 293 cells.
- IT 388088-84-4P  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)

(preparation of fused thienopyrimidines for treatment of cerebral ischemia)

RN 388088-84-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]-7-(methylsulfonyl)- (CA INDEX NAME)




IT 388088-67-3P 388088-68-4P 388088-69-5P  
 388088-72-0P 388088-76-4P 388088-78-6P  
 388088-80-0P 388088-82-2P 388088-85-5P  
 388088-87-7P 388088-88-8P 388088-89-9P  
 388088-90-2P 388088-91-3P 388088-92-4P  
 388088-93-5P 388088-94-6P 388088-95-7P  
 388088-96-8P 388088-97-9P 388088-98-0P  
 388088-99-1P 388089-00-7P 388089-01-8P  
 388089-02-9P 388089-03-0P 388089-04-1P  
 388089-05-2P 388089-06-3P 388089-07-4P  
 388089-08-5P 388089-09-6P 388089-10-9P  
 388089-12-1P 388089-13-2P 388089-14-3P  
 388089-15-4P 388089-16-5P 388089-17-6P  
 388089-19-8P 388089-21-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused thienopyrimidines for treatment of cerebral ischemia)

RN 388088-67-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

10/513699


RN 388088-68-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 388088-69-5 CAPLUS

CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-72-0 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-3-[4-[4-(1-isoquinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 388088-76-4 CAPLUS


CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

10/513699




RN 388088-78-6 CAPLUS

CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-80-0 CAPLUS


CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]-, 7-oxide (CA INDEX NAME)



RN 388088-82-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

10/513699




RN 388088-85-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-(cyclopropyl-5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-87-7 CAPLUS


CN [1]Benzo[thieno[2,3-d]pyrimidine-4,7-dione, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-88-8 CAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidine-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/513699



●2 HCl


RN 388088-89-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-(4-phenyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 388088-90-2 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-hydroxyphenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 388088-91-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/513699



● 2 HCl


RN 388088-92-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-93-5 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5,6,7,8-tetrahydro-1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-94-6 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[4-[4-[3-(trifluoromethyl)phenyl]piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 388088-95-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-96-8 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 388088-97-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-[4-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


<12/04/2007>

Erich Leese

10/513699

RN 388088-98-0 CAPLUS


CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(3-(trifluoromethyl)phenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



●2 HCl

RN 388088-99-1 CAPLUS


CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[3-[4-(3-(trifluoromethyl)phenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



●2 HCl

RN 388089-00-7 CAPLUS

CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 388089-01-8 CAPLUS

CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-

10/513699


(1-naphthalenyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 388089-02-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-03-0 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-04-1 CAPLUS

CN Benzenesulfonamide, 4-fluoro-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 388089-05-2 CAPLUS

CN Benzenesulfonamide, 3-methyl-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 388089-06-3 CAPLUS

CN Benzenesulfonamide, 4-nitro-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 388089-07-4 CAPLUS

CN Benzenesulfonamide, N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 388089-08-5 CAPLUS

CN Benzenesulfonamide, 4-amino-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 388089-09-6 CAPLUS

CN Benzenesulfonamide, 3-nitro-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 388089-10-9 CAPLUS

CN Benzenesulfonamide, 3-amino-N-[2-[3,5,6,8-tetrahydro-4-oxo-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 388089-12-1 CAPLUS  
 CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(8-quinoliny)-1-piperazinyl]ethyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 388089-11-0

CMF C24 H25 N5 O2 S




CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



RN 388089-13-2 CAPLUS


10/513699

CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 388089-14-3 CAPLUS

CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]-, 7-oxide (CA INDEX NAME)



RN 388089-15-4 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-16-5 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(methylsulfonyl)-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

10/513699




RN 388089-17-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolin-1-yl)-1-piperazinyl]ethyl]-7-(phenylsulfonyl)- (CA INDEX NAME)




RN 388089-19-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-fluorophenyl)sulfonyl]-5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolin-1-yl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 388089-21-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


IT 385821-46-5 388088-74-2 521913-49-5  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of fused thienopyrimidines for treatment of cerebral ischemia)  
 RN 385821-46-5 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 388088-74-2 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 3-(4-chlorobutyl)-6,7-dihydro- (CA INDEX NAME)




RN 521913-49-5 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




IT 388088-51-5P 388088-52-6P 388088-55-9P  
 388088-56-0P 388088-57-1P 388088-86-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of fused thienopyrimidines for treatment of cerebral ischemia)  
 RN 388088-51-5 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-  
 hydroxyethyl)- (CA INDEX NAME)



RN 388088-52-6 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-  
 tetrahydro- (CA INDEX NAME)




RN 388088-55-9 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 3-(2-chloroethyl)-6,7-  
 dihydro- (CA INDEX NAME)




RN 388088-56-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[2-[4-(3-(trifluoromethyl)phenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-57-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-86-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(4H)-carboxaldehyde, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]-4-oxo- (CA INDEX NAME)

10/513699



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:82586 CAPLUS

DOCUMENT NUMBER: 135:101920

TITLE: Thrombolysis by thienopyridines and their congeners

AUTHOR(S): Gryglewski, R. J.; Dupin, J. P.; Uracz, W.; Swies, J.;

Madej, J.; Hou, G.; Gravier, D.; Casadebaig, F.

CORPORATE SOURCE: Chair of Pharmacology, Medical College of Jagiellonian University Cracow, Pol.

SOURCE: Journal of Physiology and Pharmacology (2000), 51(4, Pt. 1), 683-693

CODEN: JPHPEI; ISSN: 0867-5910

PUBLISHER: Polish Physiological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We propose that anti-platelet thienopyridines, such as ticlopidine or clopidogrel, are thrombolytic owing to endothelial release of prostacyclin (PGI<sub>2</sub>) and tissue plasminogen activator (t-PA). In this study we used anesthetized Wistar rats with extracorporeal circulation in which thrombi that adhered to a strip of collagen were superfused with arterial blood. Weight of thrombi was continuously monitored. When administered i.v., clopidogrel or its R enantiomer deprived of anti-platelet action, both at doses of 3 mg kg<sup>-1</sup>, produced lost in weight of thrombi by 14.1±1.3% or 16.0±1.4% (n = 9), and at doses 10 mg kg<sup>-1</sup> by 28.3±2.3% or 30.4±1.9% (n = 8), resp. Maximum of thrombolysis occurred 30-45 min following the drug administration. Ticlopidine at a dose of 30 mg kg<sup>-1</sup> reduced weight of thrombi by 33.7±1.7% (n = 32). Thrombolytic action of ticlopidine was accompanied by a rise in 6-keto-PGF<sub>1α</sub> blood levels from 0.42±0.10 to 1.58±0.29 ng ml<sup>-1</sup> and t-PA antigen plasma levels from 4.70±1.00 to 12.90±1.15 ng ml<sup>-1</sup> (n = 7). Five out of eleven tested thienopyridine congeners with pyrimidine or pyrimidinone instead of pyridine rings had thrombolytic potencies similar to that of clopidogrel (ED30s at a range of 6.2-11.4 mg kg<sup>-1</sup>). A substantial increase in thrombolytic potency (ED30s at a range of 0.3-2.1 mg kg<sup>-1</sup>) was observed for congeners in which thienyl ring was condensed with an addnl. cyclopentyl, cyclohexyl or cycloheptyl structures or in which thienopyridine complex was replaced for a pyridopyrimidine one. We claim that thienopyridines, independently of their delayed anti-platelet action, do produce immediate thrombolysis in vivo. This new activity emulates capacity of their native, non-metabolized mols. to release prostacyclin and tissue plasminogen activator. We have also shown that structural changes in mols. of thienopyridines may intensify their thrombolytic potency.


IT 40277-27-8 146070-98-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thrombolysis by thienopyridines and congeners in relation to prostacyclin and tissue plasminogen activator release)


RN 40277-27-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 146070-98-6 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(2-chlorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




IT 202656-47-1P 202656-48-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(thrombolysis by thienopyridines and congeners in relation to prostacyclin and tissue plasminogen activator release)


RN 202656-47-1 CAPLUS

CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 202656-48-2 CAPLUS

CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7,8,9-hexahydro-3-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:

35

THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:475949 CAPLUS

DOCUMENT NUMBER: 133:99584

TITLE: Use of 5-HT<sub>5</sub> receptor ligands for the treatment of neurodegenerative and neuropsychiatric diseases, and screening method

INVENTOR(S): Garcia-Ladona, Francisco Javi; Szabo, Laszlo; Steiner, Gerd; Hofmann, Hans-Peter

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 16 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19900673	A1	20000713	DE 1999-19900673	19990111
CA 2359357	A1	20000720	CA 2000-2359357	20000111
WO 2000041696	A1	20000720	WO 2000-EP143	20000111
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1143975	A1	20011017	EP 2000-904894	20000111
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002534466	T	20021015	JP 2000-593307	20000111
MX 2001PA06987	A	20020918	MX 2001-PA6987	20010710
US 6750221	B1	20040615	US 2001-889157	20010711
US 20040202656	A1	20041014	US 2004-836349	20040503
PRIORITY APPLN. INFO.:			DE 1999-19900673	A 19990111
			WO 2000-EP143	W 20000111
			US 2001-889157	A3 20010711

AB The invention discloses the use of 5-HT<sub>5</sub> receptor ligands for the treatment of neurodegenerative and/or neuropsychiatric diseases, which in particular can occur with cerebral ischemia, stroke, epilepsy, and attacks generally, chronic schizophrenia, other psychotic illnesses, dementia, in particular Alzheimer dementia, demyelinating diseases, in particular multiple sclerosis, and brain tumors. The invention also discloses methods for the identification and characterization of such ligands, in particular in the form of screening methods.


IT 217487-25-7P 281657-26-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (5-HT<sub>5</sub> receptor ligand for treatment of neurodegenerative and neuropsychiatric disease, and screening method)

RN 217487-25-7 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/513699



● 2 HCl

RN 281657-26-9 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L7 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:475944 CAPLUS

DOCUMENT NUMBER: 133:89541

TITLE: Preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia

INVENTOR(S): Steiner, Gerd; Schellhaas, Kurt; Lubisch, Wilfried; Holzenkamp, Uta; Starck, Dorothea; Knopp, Monika; Szabo, Laszlo; Emling, Franz; Garcia-Ladona, Francisco Javi; Hofmann, Hans-Peter; Unger, Liliane

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 26 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19900545	A1	20000713	DE 1999-19900545	19990111
CA 2359253	A1	20000720	CA 1999-2359253	19991224
WO 2000041695	A1	20000720	WO 1999-EP10369	19991224
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1140096	A1	20011010	EP 1999-967980	19991224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916887	A	20011120	BR 1999-16887	19991224
TR 200102008	T2	20011221	TR 2001-2008	19991224
HU 2002001149	A2	20020729	HU 2002-1149	19991224
HU 2002001149	A3	20030728		
JP 2002534465	T	20021015	JP 2000-593306	19991224
NZ 512767	A	20030530	NZ 1999-512767	19991224
ZA 2001005475	A	20021003	ZA 2001-5475	20010703
MX 2001PA06967	A	20020410	MX 2001-PA6967	20010709
NO 2001003409	A	20010830	NO 2001-3409	20010710
BG 105689	A	20020228	BG 2001-105689	20010710
US 6387912	B1	20020514	US 2001-889162	20010711
PRIORITY APPLN. INFO.:			DE 1999-19900545	A 19990111
			WO 1999-EP10369	W 19991224

OTHER SOURCE(S): MARPAT 133:89541

GI



AB Thienopyrimidines I [A = O, NH; B = H, Me; D = Me, E = (un)substituted CONH2; DE = CH2CH2NR1CH2, CH2NR1CH2, CH2NR1CH2CH2; YZ = (CH2)mN, (CH2)mCH, CH2CH2C; m = 1-3; R1 = H, alkyl, Ac, Bz, (un)substituted phenylalkyl; R2 = (un)substituted Ph, pyridyl, pyrimidinyl, pyrazinyl] were prepared for use in the treatment of cerebral ischemia and stroke (no data). Thus, the pyrido[4',3':4,5]thieno[2,3-d]pyrimidine II was prepared from the 2-ethoxymethylenamino analog and 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine.


IT 281657-06-5 281657-08-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia)


RN 281657-06-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloro-1-methylethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 281657-08-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloropropyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




10/513699

IT 217487-50-8P 217487-52-0P 220415-18-9P  
220415-22-5P 220415-23-6P 281657-00-9P  
281657-01-0P 281657-02-1P 281657-11-2P  
281657-13-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of thienopyrimidines for use in the prophylaxis and therapy of  
cerebral ischemia)


RN 217487-50-8 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-  
tetrahydro-3-(2-hydroxyethyl)- (CA INDEX NAME)




RN 217487-52-0 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-6-  
ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 220415-18-9 CAPLUS


CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-  
[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA  
INDEX NAME)



RN 220415-22-5 CAPLUS  
 CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,  
 3,4,5,7-tetrahydro-3-(2-hydroxyethyl)-4-oxo-, ethyl ester (CA INDEX NAME)




RN 220415-23-6 CAPLUS  
 CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,  
 3-(2-chloroethyl)-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)




RN 281657-00-9 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-hydroxyethyl)-7-methyl- (CA INDEX NAME)

10/513699




RN 281657-01-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)




RN 281657-02-1 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-hydroxypropyl)-7-methyl- (CA INDEX NAME)




RN 281657-11-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-13-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




IT 220415-24-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
 USES (Uses)

(preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia)

RN 220415-24-7 CAPLUS

CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,  
 3,4,5,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-4-oxo-,  
 ethyl ester (CA INDEX NAME)




IT 204385-90-0P 204385-94-4P 204386-13-0P  
 204386-15-2P 204386-34-5P 204386-46-9P  
 204386-57-2P 217487-11-1P 217487-16-6P  
 217487-22-4P 217487-25-7P 217487-30-4P  
 217487-33-7P 217487-36-0P 217487-38-2P  
 220415-16-7P 220415-19-0P 281656-84-6P  
 281657-03-2P 281657-04-3P 281657-05-4P  
 281657-07-6P 281657-09-8P 281657-14-5P  
 281657-18-9P 281657-19-0P 281657-20-3P  
 281657-21-4P 281657-22-5P 281657-23-6P  
 281657-24-7P 281657-25-8P 281657-26-9P  
 281657-27-0P 281657-29-2P 281657-30-5P  
 281657-31-6P 281657-32-7P 281657-33-8P  
 281657-34-9P 281657-38-3P 281657-39-4P  
 281657-40-7P 281657-41-8P 281657-42-9P  
 281657-43-0P 281657-44-1P 281657-45-2P  
 281657-46-3P 281657-47-4P 281657-48-5P  
 281657-49-6P 281657-50-9P 281657-51-0P  
 281657-52-1P 281657-53-2P 281657-54-3P  
 281657-55-4P 281657-56-5P 281657-57-6P  
 281657-58-7P 281657-59-8P 281657-60-1P  
 281657-61-2P 281657-62-3P 281657-63-4P  
 281657-64-5P 281657-65-6P 281657-66-7P  
 281657-67-8P 281657-68-9P 281657-69-0P

281657-70-3P 281657-71-4P 281657-72-5P  
 281657-73-6P 281657-74-7P 281657-75-8P  
 281657-76-9P 281657-77-0P 281657-78-1P  
 281657-79-2P 281657-80-5P 281657-81-6P  
 281657-82-7P 281657-83-8P 281657-84-9P  
 281657-85-0P 281657-86-1P 281657-87-2P  
 281657-88-3P 281657-90-7P 281657-91-8P  
 281657-92-9P 281657-93-0P 281657-94-1P  
 281657-95-2P 281657-96-3P 281657-99-6P  
 281658-00-2P 281658-01-3P 281658-03-5P  
 281658-04-6P 281658-05-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia)

RN 204385-90-0 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 204385-94-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 204386-13-0 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-(phenylmethyl)- (CA INDEX NAME)

NAME)




RN 204386-15-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(phenylmethyl)-3-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 204386-34-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 204386-46-9 CAPLUS


CN Benzonitrile, 2-[4-[3-(5,6,7,8-tetrahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)propyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 204386-57-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(phenylmethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 217487-11-1 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 217487-16-6 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-


10/513699

tetrahydro-3-[2-[4-(2-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 217487-22-4 CAPLUS  
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-  
tetrahydro-3-[2-[4-(2-methyl-1-naphthalenyl)-1-piperazinyl]ethyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 217487-25-7 CAPLUS  
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-  
tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride  
(9CI) (CA INDEX NAME)



● 2 HCl


RN 217487-30-4 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-6-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 217487-33-7 CAPLUS


CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 217487-36-0 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(5,6,7,8-tetrahydro-1-naphthalenyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 217487-38-2 CAPLUS  
 CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-3-[2-(hexahydro-4-(1-naphthalenyl)-1H-1,4-diazepin-1-yl)ethyl]-5,6,7,8-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 220415-16-7 CAPLUS  
 CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



RN 220415-19-0 CAPLUS  
 CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 6-ethyl-3,5,6,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




10/513699




● 3 HCl

RN 281657-04-3 CAPLUS  
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI)  
(CA INDEX NAME)



● 3 HCl

RN 281657-05-4 CAPLUS  
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[1-methyl-2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 281657-07-6 CAPLUS

10/513699


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 281657-09-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2,7-dimethyl- (CA INDEX NAME)



RN 281657-14-5 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-[2-(1-naphthalenyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-18-9 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-19-0 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-20-3 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,4-dimethylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-21-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,6-dimethylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 281657-22-5 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,3-dimethylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA

INDEX NAME)



RN 281657-23-6 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,4-dimethylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-24-7 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,5-dichlorophenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



RN 281657-25-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,4-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/513699



● 2 HCl

RN 281657-26-9 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-27-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 281657-29-2 CAPLUS

<12/04/2007>

Erich Leese


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-30-5 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,5-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-31-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(4-methoxy[1,1'-biphenyl]-3-yl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)




RN 281657-32-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(2-


10/513699

methoxyphenyl)-1-(2H-pyridinyl)ethyl]-5,6,7,8-tetrahydro-7-methyl-,  
dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 281657-33-8 CAPLUS  
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(4-(2-hydroxyphenyl)-1-piperazinyl)ethyl]-7-methyl-, dihydrochloride (9CI)  
(CA INDEX NAME)




●2 HCl

RN 281657-34-9 CAPLUS  
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 281657-38-3 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 281657-39-4 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 281657-40-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,4-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 281657-41-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[3-[4-(1-naphthalenyl)-1-piperazinyl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 281657-42-9 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]- (CA INDEX NAME)

10/513699




RN 281657-43-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-44-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[3-[4-(2-methyl-1-naphthalenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-45-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,5-dichloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 281657-46-3 CAPLUS

CN Benzonitrile, 2-[4-[2-(5,6,7,8-tetrahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 281657-47-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 281657-48-5 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-49-6 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]ethyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 281657-50-9 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-51-0 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-(4-pyrazinyl-1-piperazinyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-52-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5,6,7,8-tetrahydro-1-naphthalenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-53-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,3-dihydro-1H-inden-1-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 281657-54-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-


[4-(2-methoxy-5-methyl-4-nitrophenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-55-4 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(4-isoquinoliny)-1-piperazinyl]ethyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-56-5 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4-chloro-2-methoxy-5-methylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-57-6 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,4-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-58-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(4-quinazoliny)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

10/513699

RN 281657-59-8 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-60-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 281657-61-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(1-methylethyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 281657-62-3 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-[(4-nitrophenyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 281657-63-4 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[(4-methoxyphenyl)methyl]-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 281657-64-5 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(2-phenylethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-65-6 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl]-7-(4-oxo-4-phenylbutyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-66-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-aminophenyl)methyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/513699

RN 281657-67-8 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(3-phenylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-68-9 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-7-(3-phenylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-69-0 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-70-3 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[2-(4-chlorophenyl)ethyl]-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 281657-71-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-7-(2-phenylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 281657-72-5 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-hydroxyphenyl)ethyl]-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 281657-73-6 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[2-(4-chlorophenyl)ethyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-74-7 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-[2-(1-naphthalenyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-75-8 CAPLUS


CN Benzamide, N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-76-9 CAPLUS


CN Benzamide, N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-77-0 CAPLUS


CN Benzamide, N-[3-[3,5,6,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-78-1 CAPLUS


CN Benzamide, N-[3-[3,5,6,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-79-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(4-phenylbutyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 281657-80-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-7-(4-phenylbutyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 281657-81-6 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-82-7 CAPLUS  
 CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

—OMe


RN 281657-83-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-(4-(1-naphthalenyl)-1-piperazinyl)propyl]-7-(2-phenylethyl)- (CA INDEX NAME)



RN 281657-84-9 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(2-phenylethyl)-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-85-0 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(2-phenylethyl)-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-86-1 CAPLUS


CN Benzamide, N-[3-[3,5,6,8-tetrahydro-4-oxo-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-87-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(4-phenylbutyl)-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-88-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— OMe

RN 281657-90-7 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-91-8 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-benzoyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 281657-92-9 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-benzoyl-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-93-0 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-benzoyl-5,6,7,8-tetrahydro-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-94-1 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-

[4-(2-methoxyphenyl)-1-piperazinyl]-1-methylethyl- (CA INDEX NAME)



RN 281657-95-2 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[1-methyl-2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-96-3 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-1-methylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 281657-99-6 CAPLUS


CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,

3-[2-[hexahydro-4-(1-naphthalenyl)-1H-1,4-diazepin-1-yl]ethyl]-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)




RN 281658-00-2 CAPLUS

CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-4-oxo-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-, ethyl ester (CA INDEX NAME)




RN 281658-01-3 CAPLUS

CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



RN 281658-03-5 CAPLUS


CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]propyl]-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



10/513699


RN 281658-04-6 CAPLUS

CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,  
3-[3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-3,4,5,7-tetrahydro-4-oxo-,  
ethyl ester (CA INDEX NAME)




RN 281658-05-7 CAPLUS


CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,  
3-[2-[4-(2,3-dihydro-1H-inden-4-yl)-1-piperazinyl]ethyl]-3,4,5,7-  
tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



L7 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:10812 CAPLUS  
 DOCUMENT NUMBER: 132:222501  
 TITLE: Action of amines and hydrazines on  
 N-(3-carbethoxy-2-thienyl)iminoethers: synthesis of  
 thieno[2-3-d]pyrimidin-4(3H)-ones  
 AUTHOR(S): Dridi, K.; El Efrat, M. L.; Zantour, H.  
 CORPORATE SOURCE: Lab. Synthese Organique, Campus Universitaire, Tunis,  
 Tunisia  
 SOURCE: Journal de la Societe Chimique de Tunisie (1999),  
 4(5), 387-392  
 CODEN: JSCTDP; ISSN: 0253-1208  
 PUBLISHER: Societe Chimique de Tunisie  
 DOCUMENT TYPE: Journal  
 LANGUAGE: French  
 OTHER SOURCE(S): CASREACT 132:222501  
 GI




AB N-(3-carbethoxy-2-thienyl)iminoethers [I; R1 = Ph, Me; R2 = H, Me; R1R2 = (CH2)4; R3 = H, Me, Et], obtained from 2-amino-3-carbethoxy-thiophenes, react with primary amines and hydrazines to give thieno[2,3-d]pyrimidin-4(3H)-ones (II; same R1, R2, R3; R4 = OH, benzyl, Ph, CHMePh, NH2, NHPh, NHMe, etc.). The reaction proceeds via intermediate amidines, which were isolated.  
 IT 40277-27-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (cyclocondensation of N-(3-carbethoxy-2-thienyl)iminoethers with amines and hydrazines)  
 RN 40277-27-8 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1999:116653 CAPLUS  
 DOCUMENT NUMBER: 130:168389  
 TITLE: Preparation of 3,4,5,7-tetrahydropyrrolo[3',4':4,5]thi  
 eno[2,3-d]pyrimidines as selective 5-HT1B and 5-HT1A  
 antagonists.  
 INVENTOR(S): Steiner, Gerd; Dullweber, Uta; Starck, Dorothea; Bach,  
 Alfred; Wicke, Karsten; Teschendorf, Hans-Juergen;  
 Garcia-Ladona, Francisco-javi D.; Emling, Franz  
 PATENT ASSIGNEE(S): BASF A.-G., Germany  
 SOURCE: Ger. Offen., 8 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19734444	A1	19990211	DE 1997-19734444	19970808
CA 2300391	A1	19990218	CA 1998-2300391	19980723
WO 9907711	A1	19990218	WO 1998-EP4633	19980723
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9890683	A	19990301	AU 1998-90683	19980723
AU 749539	B2	20020627		
EP 1003752	A1	20000531	EP 1998-942610	19980723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9811091	A	20000912	BR 1998-11091	19980723
TR 200000371	T2	20001121	TR 2000-371	19980723
NZ 502657	A	20010629	NZ 1998-502657	19980723
JP 2001512734	T	20010828	JP 2000-506214	19980723
HU 2001001311	A2	20010928	HU 2001-1311	19980723
HU 2001001311	A3	20021028		
CZ 290678	B6	20020911	CZ 2000-462	19980723
ZA 9807114	A	20000207	ZA 1998-7114	19980807
TW 513435	B	20021211	TW 1998-87113048	19980807
IN 1998MA01792	A	20050304	IN 1998-MA1792	19980807
MX 200001119	A	20001108	MX 2000-1119	20000201
NO 2000000605	A	20000207	NO 2000-605	20000207
US 6355647	B1	20020312	US 2000-485188	20000207
BG 104151	A	20001031	BG 2000-104151	20000210
PRIORITY APPLN. INFO.:			DE 1997-19734444	A 19970808
			WO 1998-EP4633	W 19980723
OTHER SOURCE(S):	MARPAT 130:168389			
GI				




- AB Title compds. [I; R1 = H, alkyl, Ac, (substituted) phenylalkyl, alkylcarbonyl; R2 = (substituted) Ph, pyridyl, pyrimidinyl, pyrazinyl; A = NHY, O; Y = CH2, CH2CH2, (CH2)3, CH2CH; Z = N, C, CH; n = 2-4; dotted line = optional double bond], were prepared as antidepressants (no data). Thus, 2-ethoxymethyleneamino-3,5-dicarboethoxy-4,6-dihydrothieno[3,2-c]pyrrole (preparation given) was refluxed with 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine in EtOH 3,4,5,7-tetrahydro-6-carboethoxy-3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one.
- IT 220415-16-7P 220415-17-8P 220415-18-9P  
220415-19-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of tetrahydropyrrolothienopyrimidines as selective 5-HT1B and 5-HT1A antagonists)
- RN 220415-16-7 CAPLUS
- CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-oxo-, ethyl ester (CA INDEX NAME)




- RN 220415-17-8 CAPLUS
- CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-[2-[hexahydro-4-(1-naphthalenyl)-1H-1,4-diazepin-1-yl]ethyl]-3,4,5,7-tetrahydro-4-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


10/513699




RN 220415-18-9 CAPLUS  
 CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 220415-19-0 CAPLUS  
 CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 6-ethyl-3,5,6,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




IT 220415-24-7 220415-25-8  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of tetrahydropyrrolothienopyrimidines as selective 5-HT1B and  
 5-HT1A antagonists)  
 RN 220415-24-7 CAPLUS  
 CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,  
 3,4,5,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-4-oxo-,  
 ethyl ester (CA INDEX NAME)




RN 220415-25-8 CAPLUS  
 CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-  
 [4-(1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



IT 220415-22-5P 220415-23-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of tetrahydropyrrolothienopyrimidines as selective 5-HT1B and  
 5-HT1A antagonists)  
 RN 220415-22-5 CAPLUS  
 CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,  
 3,4,5,7-tetrahydro-3-(2-hydroxyethyl)-4-oxo-, ethyl ester (CA INDEX NAME)




RN 220415-23-6 CAPLUS  
 CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,  
 3-(2-chloroethyl)-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)




L7 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1999:7999 CAPLUS  
 DOCUMENT NUMBER: 130:52437  
 TITLE: Preparation of piperazinylethylpyridothienopyrimidones  
 as antidepressants.  
 INVENTOR(S): Steiner, Gerd; Dullweber, Uta; Starck, Dorothea; Bach,  
 Alfred; Wicke, Karsten; Teschendorf, Hans-Jürgen;  
 Garcia-Ladona, Francisco-Javier; Emling, Franz  
 PATENT ASSIGNEE(S): BASF A.-G., Germany  
 SOURCE: PCT Int. Appl., 23 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856793	A1	19981217	WO 1998-EP3231	19980529
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19724979	A1	19981217	DE 1997-19724979	19970613
CA 2293440	A1	19981217	CA 1998-2293440	19980529
AU 9885357	A	19981230	AU 1998-85357	19980529
AU 748697	B2	20020613		
TR 9903061	T2	20000721	TR 1999-3061	19980529
EP 1023296	A1	20000802	EP 1998-936299	19980529
EP 1023296	B1	20031217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9810008	A	20000919	BR 1998-10008	19980529
HU 2000002736	A2	20010228	HU 2000-2736	19980529
HU 2000002736	A3	20010428		
NZ 502237	A	20010831	NZ 1998-502237	19980529
JP 2002504104	T	20020205	JP 1999-501459	19980529
AT 256686	T	20040115	AT 1998-936299	19980529
ES 2215312	T3	20041001	ES 1998-936299	19980529
TW 479059	B	20020311	TW 1998-87108721	19980603
ZA 9805120	A	19991213	ZA 1998-5120	19980612
MX 9910621	A	20000430	MX 1999-10621	19991118
NO 9906045	A	19991208	NO 1999-6045	19991208
US 6159981	A	20001212	US 1999-445178	19991208
PRIORITY APPLN. INFO.:			DE 1997-19724979	A 19970613
			WO 1998-EP3231	W 19980529

OTHER SOURCE(S): MARPAT 130:52437  
 GI




- AB Title compds. [I; R1 = H, alkyl, Ac, (substituted) phenylalkyl, phenylalkanonyl; R2 = (substituted) (benzoannellated) Ph, pyridyl, pyrimidinyl, pyrazinyl; A = NH, O; Y = CH2, CH2CH2, CH2CH2CH2, CH2CH; Z = N, C, CH; the bond between Y and Z can = double bond; n = 2, 3, 4], were prepared as antidepressants (no data). I show a high level of affinity for 5-HT1B, 5-HT1D and 5-HT1A receptors, and some I inhibit serotonin reuptake. Thus, 2-ethoxymethyleneamino-3-ethoxycarbonyl-5-ethyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (preparation given) and 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine were refluxed in EtOH to give 48% 3,4,5,6,7,8-hexahydro-6-ethyl-3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4-one hydrochloride.
- IT 217487-11-1P 217487-16-6P 217487-22-4P  
217487-25-7P 217487-30-4P 217487-33-7P  
217487-36-0P 217487-38-2P 217487-40-6P  
217487-43-9P
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of piperazinylethylpyrido[thienopyrimidones as antidepressants)
- RN 217487-11-1 CAPLUS
- CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

- RN 217487-16-6 CAPLUS
- CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/513699



● 2 HCl

RN 217487-22-4 CAPLUS


CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methyl-1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 217487-25-7 CAPLUS


CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 217487-30-4 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-6-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 217487-33-7 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 217487-36-0 CAPLUS


CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(5,6,7,8-tetrahydro-1-naphthalenyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)






●<sub>x</sub> HCl

IT 217487-50-8P 217487-52-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of piperazinylolethylpyrido[3,4':5]thieno[2,3-d]pyrimidin-4(3H)-one as antidepressants)  
 RN 217487-50-8 CAPLUS  
 CN Pyrido[3',4':5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-  
 tetrahydro-3-(2-hydroxyethyl)- (CA INDEX NAME)



RN 217487-52-0 CAPLUS  
 CN Pyrido[3',4':5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-6-  
 ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:184124 CAPLUS

DOCUMENT NUMBER: 128:217381

TITLE: Preparation of 3-substituted  
pyrido(4',3':4,5)thieno[2,3-d]pyrimidines as 5-HT1A  
receptor antagonists and serotonin reuptake inhibitors

INVENTOR(S): Steiner, Gerd; Lubisch, Wilfried; Bach, Alfred;  
Emling, Franz; Wicke, Karsten; Teschendorf,  
Hans-Juergen; Behl, Berthold; Kerrigan, Frank;  
Cheetham, Sharon

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 8 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German




FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19636769	A1	19980312	DE 1996-19636769	19960910
CA 2265509	A1	19980319	CA 1997-2265509	19970822
WO 9811110	A1	19980319	WO 1997-EP4593	19970822
W: AL, AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9742071	A	19980402	AU 1997-42071	19970822
AU 736678	B2	20010802		
EP 927184	A1	19990707	EP 1997-940118	19970822
EP 927184	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9711724	A	19990824	BR 1997-11724	19970822
CN 1230962	A	19991006	CN 1997-197765	19970822
HU 9904107	A2	20000528	HU 1999-4107	19970822
HU 9904107	A3	20011029		
NZ 334350	A	20000728	NZ 1997-334350	19970822
JP 2001500138	T	20010109	JP 1998-513191	19970822
CZ 288896	B6	20010912	CZ 1999-759	19970822
SK 283039	B6	20030204	SK 1999-230	19970822
RU 2198888	C2	20030220	RU 1999-106781	19970822
AT 252587	T	20031115	AT 1997-940118	19970822
PT 927184	T	20040331	PT 1997-940118	19970822
ES 2210570	T3	20040701	ES 1997-940118	19970822
TW 480264	B	20020321	TW 1997-86112642	19970902
IN 1997MA01971	A	20050304	IN 1997-MA1971	19970905
ZA 9708081	A	19990309	ZA 1997-8081	19970909
BG 63602	B1	20020628	BG 1999-103122	19990127
NO 9901132	A	19990309	NO 1999-1132	19990309
KR 2000035987	A	20000626	KR 1999-701939	19990309
US 6222034	B1	20010424	US 1999-254449	19990310
CN 1332168	A	20020123	CN 2001-116979	20010518
PRIORITY APPLN. INFO.:			DE 1996-19636769	A 19960910
			WO 1997-EP4593	W 19970822

OTHER SOURCE(S): CASREACT 128:217381; MARPAT 128:217381

GI




- AB The title compds. [I; R1 = H, C1-4 alkyl, Ac, (un)substituted Ph-C1-4 alkyl, etc.; R2 = (un)substituted Ph, pyridyl, pyrimidinyl, pyrazinyl, etc.; A = NH, O; X = N, CH; Y = CH2, CH2CH2, CH2CH; Z = N, C, CH; YZ bond can be double bond; n = 1-4], selective 5HT1B and 5HT1A antagonists and serotonin reuptake inhibitors (no data) useful for treatment of depressions and related diseases, were prepared by cyclocondensation of tetrahydrothienopyridines (II; R1 as defined above, R3 = cyano, C1-3 alkyl carboxylate group; R4 = C1-3 alkyl) with primary amines (III; R2, X, Y, Z, n as defined above). For example, refluxing 46.0 g 2-amino-3-cyano-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine in 250 mL HC(OEt)3 containing 3.5 mL Ac2O for 4 h under N gave 45.4 g 2-ethoxymethyleneamino-3-cyano-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine (m. 88-89°). This (3.0 g) was refluxed for 3 h with 3.3 g 1-(2-aminoethyl)-4-(o-methoxyphenyl)piperazine in 60 mL EtOH and the product salified to give 3.6 g 3,4,5,6,7,8-hexahydro-7-methyl-3-[2-(4-(o-methoxyphenyl)-1-piperazino)ethyl]pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-imine-3HCl (decomposition 282-284°).
- IT 204385-90-0P 204385-94-4P 204386-13-0P  
204386-15-2P 204386-34-5P 204386-46-9P  
204386-57-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyridothienopyrimidines as 5-HT1A receptor antagonists and serotonin reuptake inhibitors)
- RN 204385-90-0 CAPLUS  
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 204385-94-4 CAPLUS


CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 204386-13-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-(phenylmethyl)- (CA INDEX NAME)




RN 204386-15-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(phenylmethyl)-3-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 204386-34-5 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 204386-46-9 CAPLUS


CN Benzonitrile, 2-[4-[3-(5,6,7,8-tetrahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)propyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HC1

RN 204386-57-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(phenylmethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


IT 204385-92-2P 204385-97-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridothienopyrimidines as 5-HT<sub>1A</sub> receptor antagonists and serotonin reuptake inhibitors)


RN 204385-92-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[4-(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 204385-97-7 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-methyl- (CA INDEX NAME)



L7 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:66092 CAPLUS

DOCUMENT NUMBER: 128:149581

TITLE: Heterocyclic compounds with thrombolytic activity, preparation, and use for treating thrombosis

INVENTOR(S): Dupin, Jean-Pierre; Gryglewsky, Richard; Gravier, Denis; Casadebaig, Francoise; Hou, Genevieve

PATENT ASSIGNEE(S): Dupin, Jean-Pierre, Fr.; Gryglewsky, Richard; Gravier, Denis; Casadebaig, Francoise; Hou, Genevieve

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9802162	A1	19980122	WO 1997-FR1278	19970711
W: AU, CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2750862	A1	19980116	FR 1996-8969	19960712
FR 2750862	B1	19981016		
CA 2260965	A1	19980122	CA 1997-2260965	19970711
AU 9736968	A	19980209	AU 1997-36968	19970711
EP 912180	A1	19990506	EP 1997-933710	19970711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1228701	A	19990915	CN 1997-197579	19970711
JP 2000514447	T	20001031	JP 1998-505674	19970711
PRIORITY APPLN. INFO.:			FR 1996-8969	A 19960712
			WO 1997-FR1278	W 19970711

OTHER SOURCE(S): MARPAT 128:149581

AB Heterocyclic compds. (Markush included) are provided for the preparation of medicines for treating thrombosis. Preparation and biol. activity of e.g. 3-benzyl-1,2-dihydrocyclohepta[b]thieno[2,3-d]pyrimidin-4(3H)-one are presented.


IT 202656-47-1P 202656-48-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction; heterocyclic compds. with thrombolytic activity, preparation, and use for treating thrombosis)

RN 202656-47-1 CAPLUS

CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)




RN 202656-48-2 CAPLUS

CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7,8,9-hexahydro-3-

10/513699

(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:984855 CAPLUS

DOCUMENT NUMBER: 124:175999

ORIGINAL REFERENCE NO.: 124:32639a,32642a

TITLE: Synthesis and effect of gamma radiation on some sulfur-containing 3-substituted-4-oxo-2,4,5,6,7,8-hexahydrobenzo[b]thieno[2,3-d]pyrimidines of biological interest

AUTHOR(S): Ghorab, M. M.; Abdel Hamide, S. G.

CORPORATE SOURCE: National Center for Radiation Research, Technology Atomic Energy Authority, Cairo, Egypt

SOURCE: Phosphorus, Sulfur and Silicon and the Related Elements (1995), 106(1-4), 9-20  
CODEN: PSSLEC; ISSN: 1042-6507



PUBLISHER: Gordon &amp; Breach

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:175999


GI



- AB Condensation of 4-oxo-3,4,5,6,7,8-hexahydrobenzo[b]thienopyrimidine [I; R = H] with allyl bromide or Et chloroacetate gave I [R = allyl, ethoxycarbonylmethyl]. Interaction of the ester derivative I [R = ethoxycarbonylmethyl] with hydrazine hydrate furnished the hydrazide derivative I [R = CH<sub>2</sub>-CO-NHNH<sub>2</sub>] which was used as starting material for the synthesis of pyrazoles, oxadiazoles, thiosemicarbazide and hydrazone derivs., I [R = substituted pyrazolylcarbonylmethyl, substituted oxadiazolylmethyl, CH<sub>2</sub>-CO-NH-NH-C(S)-NH-R<sub>1</sub> where R<sub>1</sub> = Me, Et, phenyl; CH<sub>2</sub>-CO-NH-N:CH-R<sub>2</sub> where R<sub>2</sub> = 4-pyridinyl, 2-thienyl, p-R<sub>3</sub>-C<sub>6</sub>H<sub>4</sub> where R<sub>3</sub> = H, Me, NO<sub>2</sub>, fluoro, chloro, Br] resp. Cyclodehydration of thiosemicarbazide derivative I [R = CH<sub>2</sub>-CO-NH-NH-C(S)-NH-Ph] with sodium hydroxide resulted in the formation of the corresponding N-phenylmercaptotriazole derivative. The thiazolidinones I [R = Q where R<sub>4</sub> = Ph, p-tolyl, 4-pyridinyl, 2-thienyl] were obtained through the interaction of the hydrazone derivs. I [R = CH<sub>2</sub>-CO-NH-N:CH-R<sub>2</sub>] with mercaptoacetic acid. The obtained compds. have been characterized on the basis of their spectral (IR, PMR and Mass) data and elemental anal. Most of these compds. have been found to exhibit good antibacterial and antifungal activities. The stability of some biol. active compds. towards gamma radiation have been investigated.
- IT 40277-49-4P 162884-74-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis and effect of gamma radiation on sulfur-containing 3-substituted oxohydrobenzo[b]thieno[d]pyrimidines)


RN 40277-49-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 162884-74-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, hydrazide (CA INDEX NAME)



IT 162884-80-2P 162884-82-4P 162884-84-6P


162884-85-7P 162884-86-8P 162884-87-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and effect of gamma radiation on sulfur-containing 3-substituted oxhydrobenzo[b]thieno[d]pyrimidines)

RN 162884-80-2 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(methylamino)thioxomethyl]hydrazide (CA INDEX NAME)



RN 162884-82-4 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(phenylamino)thioxomethyl]hydrazide (CA INDEX NAME)

10/513699




RN 162884-84-6 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (phenylmethylene)hydrazide (9CI) (CA INDEX NAME)




RN 162884-85-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-methylphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 162884-86-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-87-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-fluorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




IT 40277-45-0P 162884-75-5P 162884-76-6P  
 162884-77-7P 162884-78-8P 162884-79-9P  
 162884-81-3P 162884-83-5P 162884-88-0P  
 162884-89-1P 162884-90-4P 162884-91-5P  
 173679-84-0P 173679-87-3P 173679-88-4P  
 173679-89-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and effect of gamma radiation on sulfur-containing 3-substituted oxohydrobenzo[b]thieno[d]pyrimidines)


RN 40277-45-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 162884-75-5 CAPLUS

CN 1H-Pyrazole, 3,5-dimethyl-1-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 162884-76-6 CAPLUS

CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 162884-77-7 CAPLUS

CN 3,5-Pyrazolidinedione, 1-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 162884-78-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]- (CA INDEX NAME)




RN 162884-79-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4,5-dihydro-5-thioxo-1,3,4-oxadiazol-2-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 162884-81-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(ethylamino)thioxomethyl]hydrazide (CA INDEX NAME)




RN 162884-83-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 162884-88-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-chlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-89-1 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-bromophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-90-4 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (4-pyridinylmethylene)hydrazide (9CI) (CA INDEX NAME)

10/513699




RN 162884-91-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (2-thienylmethylene)hydrazide (9CI) (CA INDEX NAME)




RN 173679-84-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-, N-(5-oxo-2-phenyl-3-thiazolidinyl)- (CA INDEX NAME)



RN 173679-87-3 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-, N-(4-methylphenyl)-5-oxo-3-thiazolidinyl- (CA INDEX NAME)



RN 173679-88-4 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-, N-[5-oxo-2-(4-pyridinyl)-3-thiazolidinyl]- (CA INDEX NAME)

10/513699




RN 173679-89-5 CAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-[5-oxo-2-(2-thienyl)-3-thiazolidinyl]- (CA INDEX NAME)




L7 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1995:402279 CAPLUS  
 DOCUMENT NUMBER: 122:314510  
 ORIGINAL REFERENCE NO.: 122:57197a,57200a  
 TITLE: Synthesis of some new 3-substituted-4-oxo-3,4,5,6,7,8-hexahydrobenzo[b]thieno [2,3-d]pyrimidines of biological interest  
 AUTHOR(S): Ghorab, M. M.; Hamide, S. G. Abdel  
 CORPORATE SOURCE: National Center Radiation Research and Technology, Atomic Energy Authority, Cairo, Egypt  
 SOURCE: Indian Journal of Heterocyclic Chemistry (1994), 4(2), 103-6  
 CODEN: IJCHEI; ISSN: 0971-1627  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB Condensation of 4-oxo-3,4,5,6,7,8-hexahydrobenzo[b]thieno[2,3-d]pyrimidine with Et chloroacetate gave (I). Interaction of I with hydrazine hydrate furnished the hydrazide, which was used for the synthesis of pyrazoles, oxadiazoles, thiosemicarbazide and hydrazone derivs. Cyclodehydration of the thiosemicarbazide derivative with sodium hydroxide resulted in the formation of a N-phenylmercaptotriazole derivative. Most of these compds. have been found to exhibit promising antibacterial and antifungal activities.

IT 40277-49-4P 162884-74-4P 162884-82-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis of benzothienopyrimidines as bactericides and fungicides)

RN 40277-49-4 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)




RN 162884-74-4 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, hydrazide (CA INDEX NAME)



RN 162884-82-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(phenylamino)thioxomethyl]hydrazide (CA INDEX NAME)



IT 162884-75-5P 162884-76-6P 162884-77-7P

162884-78-8P 162884-79-9P 162884-80-2P

162884-81-3P 162884-83-5P 162884-84-6P

162884-85-7P 162884-86-8P 162884-87-9P

162884-88-0P 162884-89-1P 162884-90-4P

162884-91-5P 162884-92-6P 162884-93-7P


162884-94-8P 162884-95-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of benzothienopyrimidines as bactericides and fungicides)


RN 162884-75-5 CAPLUS

CN 1H-Pyrazole, 3,5-dimethyl-1-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 162884-76-6 CAPLUS

CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 162884-77-7 CAPLUS

CN 3,5-Pyrazolidinedione, 1-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 162884-78-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]- (CA INDEX NAME)



RN 162884-79-9 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4,5-dihydro-5-thioxo-1,3,4-oxadiazol-2-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 162884-80-2 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(methylamino)thioxomethyl]hydrazide (CA INDEX NAME)

10/513699




RN 162884-81-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(ethylamino)thioxomethyl]hydrazide (CA INDEX NAME)




RN 162884-83-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 162884-84-6 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (phenylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 162884-85-7 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-methylphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)

10/513699




RN 162884-86-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 162884-87-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-fluorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-88-0 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-chlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-89-1 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-bromophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)

10/513699




RN 162884-90-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (4-pyridinylmethylene)hydrazide (9CI) (CA INDEX NAME)




RN 162884-91-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (2-thienylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 162884-92-6 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-(4-oxo-2-phenyl-3-thiazolidinyl)- (CA INDEX NAME)



RN 162884-93-7 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-N-[2-(4-methylphenyl)-4-oxo-3-thiazolidinyl]-4-oxo- (CA INDEX NAME)

10/513699




RN 162884-94-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-[4-oxo-2-(4-pyridinyl)-3-thiazolidinyl]- (CA INDEX NAME)



RN 162884-95-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-[4-oxo-2-(2-thienyl)-3-thiazolidinyl]- (CA INDEX NAME)



L7 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:124483 CAPLUS

DOCUMENT NUMBER: 118:124483

ORIGINAL REFERENCE NO.: 118:21581a,21584a

TITLE: Thieno[2,3-d]pyrimidin-4(3H)-one derivatives and 1,2-dihydrogenated homologs: synthesis, enhanced in vitro antiaggregant activity for reduced compounds  
 Gravier, D.; Hou, G.; Casadebaig, F.; Dupin, J. P.; Bernard, H.; Boisseau, M.

CORPORATE SOURCE: Lab. Chim. Org., UFR Sci. Pharm., Fr.


SOURCE: Pharmazie (1992), 47(10), 754-7

CODEN: PHARAT; ISSN: 0031-7144

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Et aminobenzothiophenecarboxylate I cyclized with RCH<sub>2</sub>NH<sub>2</sub> (R = Ph, substituted Ph, cyclohexyl, 2-pyridyl, 2-furyl, etc.) to give benzothienopyrimidinones II (R<sub>12</sub> = bond) which were reduced to give II (R<sub>1</sub> = H). The platelet antiaggregation activity of II were measured and was found to be comparable and sometimes greater than that of acetylsalicylic acid with serotonin release.


IT 40277-27-8P 146070-98-6P 146070-99-7P  
 146071-00-3P 146071-01-4P 146071-02-5P  
 146071-03-6P 146071-04-7P 146071-05-8P  
 146071-06-9P 146071-07-0P 146071-08-1P  
 146071-09-2P 146071-10-5P 146071-11-6P  
 146071-12-7P 146071-13-8P 146071-14-9P  
 146071-15-0P 146071-16-1P 146071-17-2P  
 146071-18-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, reduction, and platelet antiaggregation activity of)

RN 40277-27-8 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



10/513699


RN 146070-98-6 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(2-chlorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 146070-99-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 146071-00-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)



RN 146071-01-4 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 146071-02-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(4-methylphenyl)methyl]- (CA INDEX NAME)


10/513699




RN 146071-03-6 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(2-fluorophenyl)methyl]-  
5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-04-7 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(3-fluorophenyl)methyl]-  
5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 146071-05-8 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4-fluorophenyl)methyl]-  
5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 146071-06-9 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(2-  
methoxyphenyl)methyl]- (CA INDEX NAME)

10/513699




RN 146071-07-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 146071-08-1 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 146071-09-2 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(cyclohexylmethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 146071-10-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(6,6-dimethylbicyclo[3.1.1]hept-1-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)


10/513699




RN 146071-11-6 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(2-chlorophenyl)ethyl]-  
5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-12-7 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(3-  
phenylpropyl)- (CA INDEX NAME)




RN 146071-13-8 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(1,3-benzodioxol-5-ylmethyl)-  
5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 146071-14-9 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-  
pyridinylmethyl)- (CA INDEX NAME)

10/513699




RN 146071-15-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 146071-16-1 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-thienylmethyl)- (CA INDEX NAME)



RN 146071-17-2 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-furanylmethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-18-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)

10/513699



<12/04/2007>

Erich Leese

L7 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:612435 CAPLUS

DOCUMENT NUMBER: 117:212435

ORIGINAL REFERENCE NO.: 117:36699a,36702a

TITLE: Nitriles in heterocyclic synthesis: novel routes to  
cyclopentenothienopyridines,  
cyclopentenothienopyrimidenes and  
cyclopentenopyrrolopyrazoles  
Harb, Abdel Fattah Ali

AUTHOR(S):  
CORPORATE SOURCE: Fac. Sci., Assiut Univ., Kena, Egypt

SOURCE: Egyptian Journal of Pharmaceutical Sciences (1992),  
33(1-2), 283-92


CODEN: EJPSEZ; ISSN: 0301-5068

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:212435

GI



AB Aminocyclopentenothiophenecarbonitrile I prepared via an extension to the Gewald reaction, was converted into the cyclopentenothienopyridines II (R = H, NH<sub>2</sub>) and III by treatment with acrylonitrile, malononitrile and Et cyanoacetate. I was converted into the corresponding cyclopentenothienopyrimidines IV (X = S, R<sub>1</sub> = NHPh; X = O, R<sub>1</sub> = Me, H) on treatment with Ph isothiocyanate, acetic anhydride and triethylorthoformate resp. Also the corresponding cyclopentenopyrrolopyrazole V was obtained by treating I with hydrazine hydrate.

IT 144038-81-3P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 144038-81-3 CAPLUS

CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-

10/513699


methyl- (CA INDEX NAME)




<12/04/2007>

Erich Leese

L7 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1991:81761 CAPLUS  
 DOCUMENT NUMBER: 114:81761  
 ORIGINAL REFERENCE NO.: 114:13957a,13960a  
 TITLE: Synthesis and antimicrobial activity of some substituted thieno[2,3-d]pyrimidones  
 AUTHOR(S): El-Enany, M. M.; El-Shafie, F. S.  
 CORPORATE SOURCE: Coll. Pharm., King Saud Univ., Riyadh, Saudi Arabia  
 SOURCE: Oriental Journal of Chemistry (1989), 5(2), 114-17  
 CODEN: OJCHEG; ISSN: 0970-020X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 114:81761  
 GI




AB Title compds. I [R = NHSO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>R<sub>2</sub>, R<sub>1</sub> = Me, C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>-4, R<sub>2</sub> = H, 4-Me, 2-Br; R = CH<sub>2</sub>R<sub>3</sub>, R<sub>1</sub> = H, R<sub>3</sub> = NMe<sub>2</sub>, Nt<sub>2</sub>, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, pyrrolidino, 4-methylpiperazino] were prepared I had bactericidal activity against *Neisseria* and *Bacillus subtilis*, but showed little activity against *Staphylococcus aureus* and *Escherichia coli*.  
 IT 131928-79-5P 131928-80-8P 131928-81-9P  
 131928-82-0P 131928-83-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and bactericidal activity of)  
 RN 131928-79-5 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(dimethylamino)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 131928-80-8 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(diethylamino)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)

10/513699




RN 131928-81-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[[bis(2-hydroxyethyl)amino]methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 131928-82-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(1-pyrrolidinylmethyl)- (CA INDEX NAME)




RN 131928-83-1 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)




L7 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1990:198412 CAPLUS  
 DOCUMENT NUMBER: 112:198412  
 ORIGINAL REFERENCE NO.: 112:33553a,33556a  
 TITLE: Preparation of 4-oxo-5,6,7,8-tetrahydro-7-benzylpyrido[4',3':4,5]thieno[2,3-d]pyrimidines as antiallergic agents  
 INVENTOR(S): Kretzschmar, Egon; Laban, Gunter; Meisel, Peter; Kirsten, Wolfgang; Grupe, Renate  
 PATENT ASSIGNEE(S): VEB Arzneimittelwerk, Ger. Dem. Rep.  
 SOURCE: Ger. (East), 6 pp.  
 CODEN: GEXXA8  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 272088	A1	19890927	DD 1986-289130	19860415
PRIORITY APPLN. INFO.:			DD 1986-289130	19860415
OTHER SOURCE(S):		CASREACT 112:198412; MARPAT 112:198412		
GI				



I



II

AB The title compds. (I; R = H, alkyl) were prepared as antiallergic agents (no data) by cyclocondensation of carbamoylaminothienopyrimidines II with orthoformates. Thus, II (R = Pr) was stirred 4 h at 90° with HC(OEt)<sub>3</sub> in PhMe containing POCl<sub>3</sub> to give I (R = Pr).


IT 126770-01-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as antiallergic agent)

RN 126770-01-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(phenylmethyl)-3-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/513699







● HCl

<12/04/2007>


Erich Leese

L7 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1989:23828 CAPLUS  
 DOCUMENT NUMBER: 110:23828  
 ORIGINAL REFERENCE NO.: 110:4029a,4032a  
 TITLE: Synthesis of 2-, 3- and 6-substituted  
 pyrano[4',3':4,5]-thieno-[2,3-d]pyrimidine-4-ones and  
 their anticonvulsive activity  
 AUTHOR(S): Mkrtchyan, A. P.; Kazaryan, S. G.; Noravyan, A. S.;  
 Vartanyan, S. A.; Dzhagatspanyan, I. A.; Akopyan, N.  
 E.  
 CORPORATE SOURCE: Inst. Tonk. Org. Khim., Yerevan, USSR  
 SOURCE: Armyanskii Khimicheskii Zhurnal (1987), 40(9), 581-7  
 CODEN: AYKZAN; ISSN: 0515-9628  
 JOURNAL  
 LANGUAGE: Russian  
 OTHER SOURCE(S): CASREACT 110:23828  
 GI



AB Condensation of pyranones I ( $X = O$ ,  $R = H$ ,  $R_1 = Me$ ,  $Me_2CH$ ) with  $EtO_2CCH_2CN$  gave I [ $X = C(CN)CO_2Et$ ] which were cyclized by sulfur to give thienopyrans II. Subsequent acylation gave amides III ( $R_2 = EtO$ ,  $NH_2$ ,  $R_3 = alkyl$ , chloroalkyl, cyclohexylaminomethyl, morpholinoalkyl) which underwent cyclocondensation with  $R_4NH_2$  ( $R_4 = H$ ,  $Me$ ,  $OH$ ) to give pyranothienopyrimidines IV. The latter were potential anticonvulsants (no data).

IT 118005-64-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 118005-64-4 CAPLUS  
 CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-  
 2,3,6,6-tetramethyl- (CA INDEX NAME)




10/513699


<12/04/2007>

Erich Leese

L7 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1988:21827 CAPLUS  
 DOCUMENT NUMBER: 108:21827  
 ORIGINAL REFERENCE NO.: 108:3703a,3706a  
 TITLE: Thieno compounds. Part 7. Preparation of  
 2-(arylvinyl)-3,4-dihydro-4-oxothieno[2,3-  
 d]pyrimidines  
 AUTHOR(S): Thieno-Verbindungen, Ueber  
 CORPORATE SOURCE: Sekt. Pharm., Martin-Luther-Univ. Halle-Wittenberg,  
 Halle/Saale, Ger. Dem. Rep.  
 SOURCE: Pharmazie (1987), 42(2), 131  
 CODEN: PHARAT; ISSN: 0031-7144  
 DOCUMENT TYPE: Journal  
 LANGUAGE: German  
 OTHER SOURCE(S): CASREACT 108:21827  
 GI



AB Title compds. I [R = H, Me, R1 = Me, Ph, RR1 = (CH2)4, R3 = H, Me, R3 = H,  
 p-Cl, p-NO2, m-Cl, o-Cl, m-NO2, o,o'-Cl2, m,p-Cl2] were prepared in 23-85%  
 yield by ZnCl2- catalyzed condensation of methylthienopyrimidinones II  
 with R3C6H4CHO.  
 IT 101662-28-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (condensation of, with aromatic aldehydes)  
 RN 101662-28-6 CAPLUS  
 CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,3-dimethyl-  
 (CA INDEX NAME)



L7 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:213890 CAPLUS

DOCUMENT NUMBER: 106:213890

ORIGINAL REFERENCE NO.: 106:34709a,34712a

TITLE: Thieno compounds. 6. Preparation of (3,4-dihydro-4-oxothieno[2,3-d]pyrimidin-3-yl)- and (1,2,3,4-tetrahydro-2,4-dioxothieno[2,3-d]pyrimidinyl)alkanecarboxylic acid derivatives  
Boehm, R.; Mueller, R.; Pech, R.  
Sekt. Pharm., Martin-Luther-Univ., Halle/Saale, DDR-4020, Ger. Dem. Rep.


SOURCE: Pharmazie (1986), 41(9), 661  
CODEN: PHARAT; ISSN: 0031-7144

DOCUMENT TYPE: Journal


LANGUAGE: German

OTHER SOURCE(S): CASREACT 106:213890

GI



I



II


AB Alkylation of thienopyrimidinones I [R = R1 = Me; R = H, R1 = Ph; RR1 = (CH2)4; R2 = H] with Br(CH2)nCO2Et (n = 1, 2) in presence of NaOH and TEBAC in CH2Cl2-H2O gave I [R2 = (CH2)nCO2Et; n = 1, 2]. Compound II reacted only with bromoacetate and yielded only N-3 substituted derivs.

IT 40277-49-4P 108311-86-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 40277-49-4 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)





RN 108311-86-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-propanoic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)


10/513699



L7 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1987:176319 CAPLUS  
 DOCUMENT NUMBER: 106:176319  
 ORIGINAL REFERENCE NO.: 106:28617a,28620a  
 TITLE: Heteroannulated pyrimidine-4-ones  
 AUTHOR(S): Boehm, R.  
 CORPORATE SOURCE: Sekt. Pharm., Martin-Luther-Univ. Halle-Wittenberg,  
 Halle/Saale, DDR-4020, Ger. Dem. Rep.  
 SOURCE: Pharmazie (1986), 41(6), 430  
 CODEN: PHARAT; ISSN: 0031-7144  
 DOCUMENT TYPE: Journal  
 LANGUAGE: German  
 OTHER SOURCE(S): CASREACT 106:176319  
 GI




AB Aminoalkyl derivs. I (R = piperidino) and II (R1 = R, pyrrolidino; n = 1,  
 2; R2 = H, Me) of the title pyrimidinones were prepared  
 IT 107640-96-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 107640-96-0 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(1-  
 piperidinylmethyl)- (CA INDEX NAME)



L7 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1986:168489 CAPLUS  
 DOCUMENT NUMBER: 104:168489  
 ORIGINAL REFERENCE NO.: 104:26699a,26702a  
 TITLE: 3,4-Dihydro-4-oxo-2-styrylthieno[2,3-d]pyrimidines  
 INVENTOR(S): Boehm, Ralf; Pech, Reinhard; Laban, Gunter  
 PATENT ASSIGNEE(S): Martin-Luther-Universitaet Halle-Wittenberg, Ger. Dem. Rep.  
 SOURCE: Ger. (East), 4 pp.  
 CODEN: GEXXA8  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 225993	A1	19850814	DD 1983-255595	19831012

PRIORITY APPLN. INFO.:  
 DD 1983-255595 19831012  
 GI




AB The title compds. [I: R<sub>1</sub>, R<sub>2</sub> = H, alkyl; R<sub>1</sub>R<sub>2</sub> = alkylene; R<sub>3</sub> = H, Me; R<sub>4</sub> = heteroaryl, (un)substituted aryl], potential pharmaceuticals, were prepared in 23-98% yield by heating the 2-Me derivs. II with R<sub>4</sub>CHO at .apprx.180° in the presence of ZnCl<sub>2</sub> without solvent.

IT 101662-28-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and condensation of, with benzaldehydes)

RN 101662-28-6 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,3-dimethyl-  
 (CA INDEX NAME)



L7 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:422419 CAPLUS

DOCUMENT NUMBER: 99:22419

ORIGINAL REFERENCE NO.: 99:3629a,3632a

TITLE: Thieno compounds. Part 1. Phase transfer-catalyzed alkylation of thieno[2,3-d]pyrimidin-4(3H)-ones or -2,4-diones

AUTHOR(S): Boehm, R.; Pech, R.; Schneider, E.

CORPORATE SOURCE: Sekt. Pharm., Martin-Luther-Univ. Halle-Wittenberg, Halle/Saale, DDR-4020, Ger. Dem. Rep.



SOURCE: Pharmazie (1983), 38(2), 135-6

CODEN: PHARAT; ISSN: 0031-7144

DOCUMENT TYPE: Journal

LANGUAGE: German

GI



AB The alkylthienopyrimidinones I and II [R = R1 = Me; R = Ph, R1 = H; RR1 = (CH2)4; R2 = Et, Bu, H2C:CHCH2, Cl(CH2)3, EtO2CCH2, Me] were prepared by alkylation of I and II (R2 = H) with alkyl halides in presence of Et3NCH2Ph Cl-, Bu4N+ Br-, or Bu4N+ HSO4-.


IT 40277-27-8P 40277-49-4P 81136-41-6P

86009-40-7P 86009-41-8P 86009-42-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 40277-27-8 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 40277-49-4 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)

10/513699




RN 81136-41-6 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 86009-40-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-propyl- (CA INDEX NAME)



RN 86009-41-8 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-butyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 86009-42-9 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(1,1-dimethylethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)


10/513699



<12/04/2007>


Erich Leese

L7 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1982:122732 CAPLUS  
 DOCUMENT NUMBER: 96:122732  
 ORIGINAL REFERENCE NO.: 96:20157a,20160a  
 TITLE: Thieno[2,3-d]pyrimidines as potential chemotherapeutic agents. II  
 AUTHOR(S): Ram, Vishnu J.; Pandey, Hrishi Kesh; Vlietinck, Arnold J.  
 CORPORATE SOURCE: Dep. Chem., S. C. Coll., Ballia, India  
 SOURCE: Journal of Heterocyclic Chemistry (1981), 18(7), 1277-80  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 96:122732  
 GI



AB The thiophenecarboxylate I [RR1 = (CH<sub>2</sub>)<sub>4</sub>; R = H, R1 = Et] were cyclized with HCONH<sub>2</sub> to give the thienopyrimidinones II, which were chlorinated and the thienopyrimidines III (R<sub>2</sub> = Cl) aminated to give III (R<sub>3</sub> = substituted anilines). III [RR1 = (CH<sub>2</sub>)<sub>4</sub>, R<sub>2</sub> = Cl] was treated with H<sub>2</sub>NNH<sub>2</sub> followed by PhCHO to give III [RR1 = (CH<sub>2</sub>)<sub>4</sub>, R<sub>2</sub> = PhCH:NNH], which underwent cyclization to give the triazolopyrimidinobenzothiophene IV. I [RR1 = (CH<sub>2</sub>)<sub>4</sub>] was cyclized with R<sub>3</sub>NCS (R<sub>3</sub> = Ph, PhCH<sub>2</sub>) to give the thienopyrimidines V, which were converted to the S-alkyl derivs. III [RR1 = (CH<sub>2</sub>)<sub>4</sub>, R<sub>2</sub> = 2-oxo-3-pyrrolidinylmethylenehydrazino] showed some herbicidal activity against velvet leaf (20%).  
 IT 81136-41-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation of)  
 RN 81136-41-6 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)

10/513699



L7 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1982:35188 CAPLUS

DOCUMENT NUMBER: 96:35188

ORIGINAL REFERENCE NO.: 96:5821a,5824a

TITLE: Synthesis of 2-methyl-3-aryl- or -arylalkyl-5,6-dimethyl- or -polymethylenethieno[2,3-d]pyrimidin-4-ones

AUTHOR(S): Kulshreshtha, M. J.; Bhatt, Shailendra; Pardasani, Madhuri; Khanna, N. M.

CORPORATE SOURCE: Cent. Drug Res. Inst., Lucknow, India

SOURCE: Journal of the Indian Chemical Society (1981), 58(10), 982-4


CODEN: JICSAH; ISSN: 0019-4522

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 96:35188

GI



AB The acetamidothiophenecarboxylic acids I [R = Me, R<sub>2</sub> = (CH<sub>2</sub>)<sub>n</sub> (n = 3, 4, 5)] were cyclized to give the thienooxazines II, which were treated with primary amines to give the title compds. III (R<sub>1</sub> = Ph, o-FC<sub>6</sub>H<sub>4</sub>, PhCH<sub>2</sub>CH<sub>2</sub>, 3-piperidinopropyl, o-MeC<sub>6</sub>H<sub>4</sub>, etc. (55 compds). A few III showed weak diuretic, hypotensive, and antiinflammatory activity.

IT 35973-86-5P 57098-17-6P 80414-23-9P

80414-24-0P 80414-33-1P 80414-34-2P


80414-35-3P 80414-36-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 35973-86-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-(2-phenylethyl)- (CA INDEX NAME)




10/513699


RN 57098-17-6 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(diethylamino)ethyl]-  
5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)




RN 80414-23-9 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(4-methoxyphenyl)ethyl]-2-methyl- (CA INDEX NAME)



RN 80414-24-0 CAPLUS  
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(3,4-dimethoxyphenyl)ethyl]-  
5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)




RN 80414-33-1 CAPLUS  
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3-[2-(diethylamino)ethyl]-  
3,5,6,7,8,9-hexahydro-2-methyl- (CA INDEX NAME)




RN 80414-34-2 CAPLUS  
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7,8,9-hexahydro-2-methyl-3-(2-phenylethyl)- (CA INDEX NAME)

10/513699




RN 80414-35-3 CAPLUS

CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7,8,9-hexahydro-3-[2-(4-methoxyphenyl)ethyl]-2-methyl- (CA INDEX NAME)




RN 80414-36-4 CAPLUS


CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3-[2-(3,4-dimethoxyphenyl)ethyl]-3,5,6,7,8,9-hexahydro-2-methyl- (CA INDEX NAME)



L7 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1981:47256 CAPLUS  
 DOCUMENT NUMBER: 94:47256  
 ORIGINAL REFERENCE NO.: 94:7713a,7716a  
 TITLE: Synthesis of some substituted thienopyrimidiones  
 AUTHOR(S): El-Telbany, Farag A.  
 CORPORATE SOURCE: Fac. Pharm., Univ. Cairo, Cairo, Egypt  
 SOURCE: Pharmazie (1980), 35(5-6), 326-7  
 CODEN: PHARAT; ISSN: 0031-7144  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 94:47256  
 GI




AB Thienopyrimidinones I [X = NPr, NBu, NCH<sub>2</sub>CHMe<sub>2</sub>, cyclohexylamino, 1-naphthylamino, NC<sub>6</sub>H<sub>4</sub>I-4, NC<sub>6</sub>H<sub>4</sub>OEt-4, NC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>Et-4, NC<sub>6</sub>H<sub>4</sub>OH-4, 4-pyridylamino, 3,4-RCH<sub>2</sub>(HO)C<sub>6</sub>H<sub>3</sub>N, R = NEt<sub>2</sub>, N(CH<sub>2</sub>Ph)<sub>2</sub>, piperidino, 4-methylpiperazino, morpholino] were obtained in 35-85% yield by aminolysis of I (X = O).  
 IT 76226-43-2P 76226-44-3P 76226-45-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 76226-43-2 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-propyl- (CA INDEX NAME)




RN 76226-44-3 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-butyl-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)

10/513699





RN 76226-45-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-(2-methylpropyl)- (CA INDEX NAME)



L7 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1979:186894 CAPLUS  
 DOCUMENT NUMBER: 90:186894  
 ORIGINAL REFERENCE NO.: 90:29697a,29700a  
 TITLE: Thieno[2,3-d]pyrimidines as potential chemotherapeutic agents  
 AUTHOR(S): Ram, Vishnu Ji  
 CORPORATE SOURCE: Dep. Chem., S. C. Coll., Ballia, India  
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1979), 312(1), 19-25  
 CODEN: ARPMAS; ISSN: 0365-6233  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 90:186894  
 GI




AB Thienopyrimidines I (R = Cl, SH, NHH2, pyrrolidinoethylamino, morpholinopropylamino, HOCH2CH2NH, (HOCH2CH2)2N, 2-ClC6H4CH2NH, 4-ClC6H4CH2NH, 2,4-Cl2C6H3CH2NH, 2-FC6H4NH, 3-FC6H4NH, 4-FC6H4NH, 4-Et2NC6H4NH, piperidino, OEt, morpholino), II (X = N, CH, CSH, CMeCO), and related compds. were prepared from 4-oxo-5,6,7,8-tetrahydrothianaphtheno[2,3-d]pyrimidine. I (R = Cl) were herbicidal at 8 lb/acre. I (R = SH, NHH2, NHC6H4F-2, NHC6H4F-3, NHC6H4NEt2-4) were bactericidal against *Streptococcus faecalis* at 64 ppm. I (R = 2,4-Cl2C6H3CH2NH, 2-FC6H4NH) were fungicidal against *Pythium* at 64 ppm, but that was accompanied by phytotoxicity.

IT 40277-29-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 40277-29-0 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-methyl-  
 (CA INDEX NAME)




L7 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1977:502375 CAPLUS  
 DOCUMENT NUMBER: 87:102375  
 ORIGINAL REFERENCE NO.: 87:16259a,16262a  
 TITLE: 3-( $\alpha$ -Alkyl substituted)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidine derivatives  
 INVENTOR(S): Madronero Pelaez, Ramon; Vega Noverola, Salvador; Del Rio Zambrana, Joaquin; Martinez Roldan, Cristobal  
 PATENT ASSIGNEE(S): Laboratorios Made S. A., Spain  
 SOURCE: Span., 17 pp.  
 CODEN: SPXXAD  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Spanish  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 425699	A1	19760701	ES 1974-425699	19740426
PRIORITY APPLN. INFO.: GI			ES 1974-425699 A	19740426




AB Thieno[3,2-d]pyrimidinones I [2 = Me<sub>2</sub>N, Et<sub>2</sub>N, iso-PrO, morpholino, 1-pyrrolidinyl; n = 2,3; R<sup>1</sup> = Me, R<sup>2</sup> = H; or R<sup>1</sup>R<sup>2</sup> = (CH<sub>2</sub>)<sub>4</sub> or (CH<sub>2</sub>)<sub>5</sub>] were prepared by treatment of the thieno[3,2-d](3,1)oxazinones II with amines R(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>. The ring-opened compds. III were intermediates in some cases. Thus an equimolar mixture of II (R<sup>1</sup> = Me, R<sup>2</sup> = H) and 2-morpholinoethylamine in benzene was heated 18 h at 130° to give III (R = morpholino, n = 2, R<sup>1</sup> = Me, R<sup>2</sup> = H), which with polyphosphoric acid at 100° for 3 h and neutralization with 20% aqueous NaOH gave I (same substituents).  
 IT 57098-15-4P 57098-21-2P 63826-32-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 57098-15-4 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

10/513699




RN 57098-21-2 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 63826-32-4 CAPLUS

CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3-[3-(dimethylamino)propyl]-3,5,6,7,8,9-hexahydro-2-methyl- (CA INDEX NAME)




L7 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1977:423197 CAPLUS  
 DOCUMENT NUMBER: 87:23197  
 ORIGINAL REFERENCE NO.: 87:3673a,3676a  
 TITLE: Thiophene bioisosteres. Synthesis of  
 2-methyl-4-oxothieno [2,3-d] pyrimidines  
 AUTHOR(S): Noverola, Salvador Vega  
 CORPORATE SOURCE: Spain  
 SOURCE: Anales de la Real Academia de Farmacia (1976), 42(4),  
 563-607  
 CODEN: ARAFAY; ISSN: 0034-0618  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Spanish  
 OTHER SOURCE(S): CASREACT 87:23197  
 GI




AB Thienopyrimidinones I [RR1 = (CH2)4, R = Me, R1 = H; R2 = (CH2)3OCHMe2, NHCO2Et, NHCOCH2Ph, NHBz, (CH2)nNR3R4, n = 2, 3, NR3R4 = NMe2, NEt2, morpholino, pyrrolidino] were prepared by treating cyclohexanone and S or HSCH2C(=O)Me with NCCH2CO2Et, acetylating II (R5 = H, R6 = Et), hydrolyzing, cyclizing II (R5 = Ac, R6 = H) with Ac2O, and treating the oxazines III with R2NH2 with prolonged heating. Intermediates IV of the reaction of III with R2NH2 were isolated at shorter reaction times.  
 IT 57098-21-2P 57098-22-3P 57098-23-4P  
 63003-61-2P 63003-62-3P 63003-63-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 57098-21-2 CAPLUS  
 CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

10/513699




RN 57098-22-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 57098-23-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)




RN 63003-61-2 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(4-morpholinyl)ethyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 57098-15-4

CMF C17 H23 N3 O2 S




CM 2

CRN 110-16-7

10/513699

CMF C4 H4 O4

Double bond geometry as shown.




RN 63003-62-3 CAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(diethylamino)ethyl]-5,6,7,8-tetrahydro-2-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 57098-17-6

CMF C17 H25 N3 O S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 63003-63-4 CAPLUS


CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(diethylamino)propyl]-5,6,7,8-tetrahydro-2-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 57098-19-8

CMF C18 H27 N3 O S

10/513699




CM 2





CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



L7 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1977:405893 CAPLUS  
 DOCUMENT NUMBER: 87:5893  
 ORIGINAL REFERENCE NO.: 87:949a,952a  
 TITLE: Heterocyclic compounds. VIII. Synthesis of 3- and 2,3-substituted thienopyrimidones  
 AUTHOR(S): Manhas, M. S.; Amin, S. G.  
 CORPORATE SOURCE: Dep. Chem. Chem. Eng., Stevens Inst. Technol., Hoboken, NJ, USA  
 SOURCE: Journal of Heterocyclic Chemistry (1977), 14(1), 161-4  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 87:5893  
 GI




AB Substituted thienopyrimidones ,e.g., I (R = Ph, PhCH<sub>2</sub>CH<sub>2</sub>) and II, and quinazolones ,e.g., III, were prepared Thus, the benzothiophene IV (R = H) was formulated to give IV (R = CHO), which was cyclized with PhNH<sub>2</sub> to give I (R = Ph).  
 IT 62821-73-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 62821-73-2 CAPLUS  
 CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-phenylethyl)- (CA INDEX NAME)



L7 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1976:560152 CAPLUS  
 Correction of: 1973:29795  
 DOCUMENT NUMBER: 85:160152  
 Correction of: 78:29795  
 ORIGINAL REFERENCE NO.: 85:25645a,25648a  
 TITLE: Benzothienopyrimidine derivatives  
 INVENTOR(S): Nakanishi, Michio; Shiraki, Masami  
 PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan  
 SOURCE: Jpn. Tokkyo Koho, 3 pp.  
 CODEN: JAXXAD  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47042271	B4	19721025	JP 1968-42845	19680620

GI



AB The central nervous depressant and antiinflammatory title compds. (I) were prepared E.g., heating 3-methyl-6,7,8,6-tetrahydro-1H-[1]benzothieno[2,3-d]-[1,3]oxazin-1-one and PhNH<sub>2</sub> 10 min at 60° gave crude crystals which stirred with dicyclohexylcarbodiimide in THF 2 hr at room temperature to gave I (R = H, R1 = Ph, R2 = Me). Similarly, the following I were prepared (R, R1, R2 given): H, p-ClC<sub>6</sub>H<sub>4</sub>, Me; H, p-MeOC<sub>6</sub>H<sub>4</sub>, Me; H, 2,3-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, Me; H, m-CF<sub>3</sub>-C<sub>6</sub>H<sub>4</sub>, Me; H, p-EtO<sub>2</sub>C, Me; Me, p-tolyl, Me; Me, PhCH<sub>2</sub>, Me; Me, Bu, Me; H, Ph, Et; and H, Et, Me.


IT 39625-79-1P 39625-82-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 39625-79-1 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,7-dimethyl-3-(phenylmethyl)- (CA INDEX NAME)



RN 39625-82-6 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-ethyl-5,6,7,8-tetrahydro-2-

10/513699

methyl- (CA INDEX NAME)



L7 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:578980 CAPLUS

DOCUMENT NUMBER: 83:178980

ORIGINAL REFERENCE NO.: 83:28109a,28112a

TITLE: Thiophene bioisosteres. II. 2-Methyl-4-oxothieno[3,2-d]pyrimidines and 2-(4H-1,2,4-triazol-4-yl)-3-carboxythiophenes

AUTHOR(S): Lorente, L.; Madronero, R.; Vega, S.

CORPORATE SOURCE: Inst. Quim. Med., Madrid, Spain

SOURCE: Anales de Quimica (1968-1979) (1974), 70(12), 974-9

CODEN: ANQUBU; ISSN: 0365-4990

DOCUMENT TYPE: Journal

LANGUAGE: Spanish

OTHER SOURCE(S): CASREACT 83:178980

GI For diagram(s), see printed CA Issue.

AB Thienopyrimidines I, thiophenes II, and triazolylthiophenes III [RR1 = (CH2)4, R = Me, R1 = H; R2 = aminoalkyl, acylamino, EtO2CNH] were prepared by treating IV with amines; the relative yields of I-III depended on conditions. IV were prepared by cyclizing 2-acetyl-amino-3-thiophenecarboxylic acids.

IT 57098-16-5P 57098-18-7P 57098-20-1P

57098-21-2P 57098-22-3P 57098-23-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 57098-16-5 CAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(4-morpholinyl)ethyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 57098-15-4

CMF C17 H23 N3 O2 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 57098-18-7 CAPLUS


10/513699

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(diethylamino)ethyl]-  
5,6,7,8-tetrahydro-2-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 57098-17-6

CMF C17 H25 N3 O S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 57098-20-1 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(diethylamino)propyl]-  
5,6,7,8-tetrahydro-2-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 57098-19-8

CMF C18 H27 N3 O S




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.

10/513699




RN 57098-21-2 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 57098-22-3 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 57098-23-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)




L7 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1973:124381 CAPLUS  
 DOCUMENT NUMBER: 78:124381  
 ORIGINAL REFERENCE NO.: 78:19979a,19982a  
 TITLE: Synthesis of new heterocycles. VI. Syntheses of certain novel condensed thiophenes  
 AUTHOR(S): Arya, V. P.  
 CORPORATE SOURCE: CIBA Res. Cent., Bombay, India  
 SOURCE: Indian Journal of Chemistry (1972), 10(12), 1141-50  
 CODEN: IJOCAP; ISSN: 0019-5103  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI For diagram(s), see printed CA Issue.  
 AB The synthesis of a number of novel condensed thiophenes from cycloalkanones (I) react with nitriles having an active methylene group in the  $\alpha$ -position to form substituted nitriles (II). These undergo facile cyclization with S in the presence of diethylamine to give the thiophenes (III). Several reactions of III were explored. For example, some III were cyclized with HC(OEt)<sub>3</sub> and Ac<sub>2</sub>O to lactams. These lactams were converted to tetracyclic heterocycles such as s-triazoles, imidazole, pyrimidine, and tetrazole derivs.  
 IT 40106-38-5P 40106-39-6P 40106-40-9P  
 40106-41-0P 40106-42-1P 40106-43-2P  
 40106-44-3P 40106-57-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 40106-38-5 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(dimethylamino)propyl]-5,6,7,8-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 40106-39-6 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(4-morpholinyl)ethyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 47198-89-0  
 CMF C16 H21 N3 O2 S

10/513699




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 40106-40-9 CAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-(1-piperidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 40106-41-0 CAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(1-pyrrolidinyl)ethyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 47130-00-7

CMF C16 H21 N3 O S



<12/04/2007>

Erich Leese


10/513699

CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 40106-42-1 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(dimethylamino)-1-methylethyl]-5,6,7,8-tetrahydro-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 47046-21-9

CMF C15 H21 N3 O S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 40106-43-2 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(hexahydro-1H-azepin-1-yl)ethyl]-5,6,7,8-tetrahydro-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 47275-94-5

CMF C18 H25 N3 O S

10/513699




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 40106-44-3 CAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(dimethylamino)propyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 40106-57-8 CAPLUS

CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3-[3-(dimethylamino)propyl]-3,5,6,7,8,9-hexahydro- (CA INDEX NAME)



L7 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:111243 CAPLUS

DOCUMENT NUMBER: 78:111243

ORIGINAL REFERENCE NO.: 78:17859a,17862a

TITLE: Synthesis of 5,6,7,8-tetrahydrobenzo[1]thieno[2,3,d]pyrimidine

AUTHOR(S): Robba, Max; Touzot, Mrs. P.; Riquelme, R. M.

CORPORATE SOURCE: Lab. Pharm. Chim., U.E.R. Sci. Pharm., Caen, Fr.

SOURCE: Comptes Rendus des Seances de l'Academie des Sciences,

Serie C: Sciences Chimiques (1973), 276(1), 93-5

CODEN: CHDCAQ; ISSN: 0567-6541

DOCUMENT TYPE: Journal

LANGUAGE: French

GI For diagram(s), see printed CA Issue.

AB The benzothienopyrimidine I (R = R1 = H) was prepared by dehalogenation of I (R = Cl, R1 = H) via I (R = NHH2, R1 = H). The benzothienopyrimidinone II (R2 = H) underwent electrophilic substitutions to give II (R2 = Me, CH2Ph, CH2CH=CH2, CH2CO2H, CH2CO2Et, CH2OH, CH2CH2CN). I (R = Cl, R1 = H, Cl) underwent nucleophilic substitutions to give I (R = OMe, OEt, OCH2CH=CH2, OPh, NH2, NHet, piperidino, morpholino, SPh, SCH2CO2Me; R1 = H) and I (R = R1 = NHH2; R = NHH2, H; R1 = Cl). I (R = NHH2, R1 = H) reacted with HCO2H, AcOH, and HNO2 to give III (X = CH, CMe, N, resp.).

IT 40277-27-8P 40277-29-0P 40277-45-0P


40277-46-1P 40277-47-2P 40277-48-3P

40277-49-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 40277-27-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-  
(phenylmethyl)- (CA INDEX NAME)



RN 40277-29-0 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-methyl-  
(CA INDEX NAME)



RN 40277-45-0 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-  
propenyl)- (9CI) (CA INDEX NAME)

10/513699




RN 40277-46-1 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)




RN 40277-47-2 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(hydroxymethyl)- (CA INDEX NAME)



RN 40277-48-3 CAPLUS


CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-propanenitrile, 5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 40277-49-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)

10/513699




<12/04/2007>


Erich Leese

L7 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1973:29795 CAPLUS  
 DOCUMENT NUMBER: 78:29795  
 ORIGINAL REFERENCE NO.: 78:4707a,4710a  
 TITLE: Benzothienopyrimidine derivatives  
 INVENTOR(S): Nakanishi, Michio; Shiraki, Masami  
 PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd.  
 SOURCE: Jpn. Tokkyo Koho, 3 pp.  
 CODEN: JAXXAD  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 48042271	B4	19721025	JP 1968-42845	19680620
GI	For diagram(s), see printed CA Issue.				
AB	The central nervous depressant and antiinflammatory title compds. (I) were prepared E.g., heating 3-methyl-6,7,8,9-tetrahydro-1H-[1]benzothieno[2,3-d]-[1,3]oxazin-1-one and PhNH <sub>2</sub> 10 min at 60° gave crude crystals which stirred with dicyclohexylcarbodiimide in THF 2 hr at room temperature to gave I (R = H, R1 = Ph, R2 = Me). Similarly, the following I were prepared (R, R1, R2 given): H, p-ClC <sub>6</sub> H <sub>4</sub> , Me; H, p-MeOC <sub>6</sub> H <sub>4</sub> , Me; H, 2,3-Me <sub>2</sub> C <sub>6</sub> H <sub>3</sub> , Me; H, m-ClC <sub>6</sub> H <sub>4</sub> , Me; H, p-EtO <sub>2</sub> C, Me; Me, p-tolyl, Me; Me, PhCH <sub>2</sub> , Me; Me, Bu, Me; H, Ph, Et; and H, Et, Me.				
IT	39625-79-1P 39625-80-4P 39625-82-6P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of)				
RN	39625-79-1 CAPLUS				
CN	[1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,7-dimethyl-3-(phenylmethyl)- (CA INDEX NAME)				




RN 39625-80-4 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-butyl-5,6,7,8-tetrahydro-2,7-dimethyl- (CA INDEX NAME)



RN 39625-82-6 CAPLUS  
 CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-ethyl-5,6,7,8-tetrahydro-2-

10/513699

methyl- (CA INDEX NAME)



L7 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:107846 CAPLUS

DOCUMENT NUMBER: 76:107846

ORIGINAL REFERENCE NO.: 76:17337a,17340a

TITLE: Heterocyclic compounds. 4. Synthesis and antiinflammatory activity of some substituted thienopyrimidones

AUTHOR(S): Manhas, M. S.; Sharma, S. D.; Amin, S. G.

CORPORATE SOURCE: Dep. Chem. Chem. Eng., Stevens Inst. Technol., Hoboken, NJ, USA

SOURCE: Journal of Medicinal Chemistry (1972), 15(1), 106-7

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Appreciable antiinflammatory activity in the carrageenan-induced edema test in mice was shown by 2-methyl-3-(p-tolyl)-4-oxo-5,6-tetramethylenethieno[2,3-d]pyrimidine (I) [34387-07-0] and the corresponding 3-(p-fluorophenyl) compound (II), which are structural analogs of biol. active substituted quinazolines. The LD50 values of I and II were 1300 and 400 mg/kg i.p., resp., and at 80 mg/kg orally they produced 29.8 and 19.9% inhibition of edema, resp. To synthesize I, 2-amino-4,5-tetramethylenethiophene-3-carboxylic acid was acetylated with Ac2O to form a lactone which was heated with an equivalent amount of p-toluidine.


IT 35973-85-4 35973-86-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiinflammatory activity of)


RN 35973-85-4 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-(phenylmethyl)- (CA INDEX NAME)



RN 35973-86-5 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-(2-phenylethyl)- (CA INDEX NAME)



10/513699

<12/04/2007>

Erich Leese

10/513699

=> d his

(FILE 'HOME' ENTERED AT 16:54:37 ON 03 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:54:48 ON 03 JUN 2008

L1 STRUCTURE UPLOADED

L2 2 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:55:18 ON 03 JUN 2008

L3 1 S L2 FULL

L4 STRUCTURE UPLOADED

S L4

FILE 'REGISTRY' ENTERED AT 16:56:01 ON 03 JUN 2008

L5 4283 S L4 FULL

FILE 'CAPLUS' ENTERED AT 16:56:03 ON 03 JUN 2008

L6 44 S L5 FULL

FILE 'CAPLUS' ENTERED AT 16:56:09 ON 03 JUN 2008

L7 44 S L6 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

241.24

604.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-35.20

-36.00

STN INTERNATIONAL LOGOFF AT 16:57:52 ON 03 JUN 2008